Perrigo (PRGO) 8-K 20 Nov 14 Cautionary Note Regarding Forward-Looking Statements Financial data

Document_and_Entity_Informatio

Document and Entity Information Document	3 Months Ended
	Sep. 27, 2014
Document and Entity Information [Abstract]	'
Entity Registrant Name	'PERRIGO CO PLC
Entity Central Index Key	'0001585364
Document Type	'8-K
Document Period End Date	27-Sep-14
Amendment Flag	'false

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Net sales	$951.50	$933.40
Cost of sales	629.7	577.1
Gross profit	321.8	356.3
Operating expenses	'	'
Distribution	14.4	13.2
Research and Development	36.6	32.3
Selling	50.4	50.2
Administration	81.5	78.8
Restructuring	1.7	2.1
Total operating expenses	184.6	176.6
Operating Income	137.2	179.7
Interest expense, net	25.9	21.4
Other expense, (income), net	2.7	1
Income before income taxes	108.6	157.3
Income tax expense	12.3	45.9
Net income	$96.30	$111.40
Earnings per share	'	'
Basic earnings per share	$0.72	$1.18
Diluted earnings per share	$0.72	$1.18
Weighted average shares outstanding	'	'
Basic	133.9	94.2
Diluted	134.4	94.7
Dividends declared per share	$0.11	$0.09

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Net income	$96.30	$111.40
Other Comprehensive Income:	'	'
Foreign currency translation adjustments	-63.8	36.6
Change in fair value of derivative financial instruments, net of tax	-2.1	-9.2
Change in fair value of investment securities, net of tax	0.6	0
Post-retirement and pension liability adjustments, net of tax	0	-0.1
Other Comprehensive Income (Loss), Net of Tax	-65.3	27.3
Comprehensive income	31	138.7
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax	-1.1	-4.6
Other Comprehensive Income (Loss), Available-for-sale Securities, Tax	0.3	0
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax	$0	$0

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 27, 2014	Jun. 28, 2014
In Millions, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$891.50	$799.50
Investment securities	21.6	5.9
Accounts Receivable, Net	869.4	935.1
Inventories	656.8	631.6
Current deferred income taxes	64.6	62.8
Prepaid expenses and other current assets	130.1	116
Total current assets	2,634	2,550.90
Non-current assets	'	'
Property and Equipment, Net	761.7	779.9
Goodwill and other indefinite-lived intangible assets	3,503	3,543.80
Other intangible assets, net	6,671.80	6,787
Non-current deferred income taxes	28.5	23.6
Other non-current assets	182	195
Total non-current assets	11,147	11,329.30
Total Assets	13,781	13,880.20
Current liabilities	'	'
Accounts Payable	309	364.3
Short-term Debt	0	2.1
Payroll and related taxes	77	112.3
Accrued Customer Programs	274.5	256.5
Accrued Liabilities	179.9	179.4
Accrued Income Taxes	31.7	17.4
Current deferred income taxes	4.3	1.1
Current portion of long-term debt	141.5	141.6
Total current liabilities	1,017.90	1,074.70
Non-current liabilities	'	'
Long-term debt, less current portion	3,050.80	3,090.50
Non-current deferred income taxes	708.7	727.9
Other non-current liabilities	286.9	293.4
Total non-current liabilities	4,046.40	4,111.80
Liabilities	5,064.30	5,186.50
Commitments and Contingencies	0	0
Controlling interest:	'	'
Preferred shares, $0.0001 par value, 10 million shares authorized	0	0
Common stock, €0.0001 par value, 10 billion shares authorized	6,685.20	6,678.20
Accumulated other comprehensive income	74.3	139.6
Retained earnings	1,957.20	1,875.10
Total shareholders' equity	8,716.70	8,692.90
Noncontrolling interest	0	0.8
Shareholders' equity	8,716.70	8,693.70
Total liabilities and shareholders' equity	$13,781	$13,880.20
Supplemental Disclosures of Balance Sheet Information	'	'
Preferred shares, issued and outstanding	0	0
Ordinary shares, issued and outstanding	133.9	133.8

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical)	Sep. 27, 2014	Sep. 27, 2014	Jun. 28, 2014	Jun. 28, 2014
In Millions, except Per Share data, unless otherwise specified	USD ($)	EUR (€)	USD ($)	EUR (€)
Shareholders' Equity	'	'	'	'
Preferred shares, issued	0	0	0	0
Preferred shares outstanding	0	0	0	0
Ordinary shares issued	133.9	133.9	133.8	133.8
Ordinary shares, outstanding	133.9	133.9	133.8	133.8
Preferred shares, par value	$0.00	'	$0.00	'
Preferred shares, authorized	10	10	10	10
Ordinary shares, par value	'	€ 0.00	'	€ 0.00
Ordinary shares, authorized	10,000	10,000	10,000	10,000
Allowance for Doubtful Accounts Receivable	$2.60	'	$2.70	'
Commitments and Contingencies	$0	'	$0	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Cash Flows From (For) Operating Activities	'	'
Net income	$96.30	$111.40
Adjustments to derive cash flows	'	'
Depreciation and amortization	126.6	47.7
Share-based Compensation	8.8	5.9
Unrealized loss on equity method investments	3.1	0
Non-cash restructuring charges	1.7	1.9
Income tax benefit from exercise of stock options	1.5	1.8
Excess Tax Benefit of stock transactions	4.3	7.2
Deferred Income Taxes	-20.1	-14.6
Subtotal	213.6	146.9
Changes in operating assets and liabilities, net of acquisitions	'	'
Accounts receivable	57.3	-45.7
Inventories	-29.7	-12
Accounts payable	-32.5	-67.6
Payroll and related taxes	-34.9	-8.6
Accrued customer programs	18.1	27.5
Accrued liabilities	0.6	21.2
Accrued income taxes	14.6	34.6
Other	-12	2.4
Subtotal	-18.5	-48.2
Net cash from operating activities	195.1	98.7
Cash Flows (For) From Investing Activities	'	'
Additions to property and equipment	-31.7	-40.4
(Purchase) return of Investments	-0.1	0
Proceeds from sale of business	1.1	0
Proceeds from sale of land	0	4.6
Net cash from (for) investing activities	-30.7	-35.8
Cash Flows (For) From Financing Activities	'	'
Repayments of long-term debt	-39.5	0
Cash dividends	-14.1	-8.5
Repurchase of common stock	-7.5	-7.3
Settlements of contingent consideration	-5	0
Borrowings (repayments) of short-term debt, net	-2.1	1.1
Issuance of Common Stock	2.6	3.5
Excess tax benefit of stock transactions	4.3	7.2
Deferred financing fees	0	-24.8
Net cash from (for) financing activities	-61.3	-28.8
Effect of exchange rate changes on cash	-11.1	2.6
Net decrease in cash and cash equivalents	92	36.7
Cash and cash equivalents, beginning of period	799.5	779.9
Cash and cash equivalents, end of period	891.5	816.6
Cash paid/received during the period for:	'	'
Interest paid	5.2	1.7
Interest received	0.2	0.2
Income taxes paid	10.9	22.1
Income taxes refunded	$0.50	$0.80

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 27, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies and Change in Accounting Principles [Text Block]	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The Company
	Perrigo Company plc (formerly known as Perrigo Company Limited, and prior thereto, Blisfont Limited) ("Perrigo" or "the Company"), was incorporated under the laws of Ireland on June 28, 2013, and became the successor registrant of Perrigo Company on December 18, 2013 in connection with the consummation of the acquisition of Elan Corporation, plc ("Elan"), which is discussed further in Note 2. From its beginnings as a packager of home remedies in 1887, Perrigo has grown to become a leading global healthcare supplier. Perrigo develops, manufactures, and distributes over-the-counter ("OTC") and generic prescription ("Rx") pharmaceuticals, nutritional products, and active pharmaceutical ingredients ("API"), and has a specialty sciences business comprised of assets focused predominantly on the treatment of Multiple Sclerosis (Tysabri®). The Company is the world's largest manufacturer of OTC healthcare products for the store brand market. Perrigo's mission is to offer uncompromised "Quality Affordable Healthcare Products®", and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel, and Australia, as well as many other key markets worldwide, including Canada, China, and Latin America.
	Basis of presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes included in Perrigo Company plc's Annual Report on Form 10-K for the year ended June 28, 2014. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation have been included.
	The Company’s sales of OTC pharmaceutical products are subject to the seasonal demands for cough/cold/flu and allergy products and consumer dynamics in the retail environments in which our customers operate. In addition, the Company's animal health products are subject to the seasonal demand for flea and tick products, which typically peaks during the warmer weather months. Accordingly, operating results for the three months ended September 27, 2014 are not necessarily indicative of the results that may be expected for a full fiscal year.
	Principles of consolidation
	The condensed consolidated financial statements include the accounts of the Company, all majority-owned subsidiaries, and for the three months ended September 28, 2013, a variable-interest entity ("VIE"). Activities related to the VIE were immaterial. All intercompany transactions and balances have been eliminated in consolidation.
	Recently adopted accounting standards
	In July 2013, the Financial Accounting Standards Board issued Accounting Standards Update 2013-11, "Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists" ("ASU 2013-11"). The amendments in ASU 2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The Company prospectively adopted this guidance in fiscal 2015, and has presented $90.2 million as a reclassification from Non-current deferred income taxes to Other non-current liabilities on the Condensed Consolidated Balance Sheets.

Business_Acquisitions_Notes

Business Acquisitions (Notes)	3 Months Ended
	Sep. 27, 2014
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	ACQUISITIONS
	All of the below acquisitions, with the exception of the Vedants transaction, have been accounted for under the acquisition method of accounting, and the related assets acquired and liabilities assumed were recorded at fair value as of the acquisition date. Fair value estimates are based on a complex series of judgments about future events and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets and liabilities assumed, as well as asset lives, can materially impact the Company's results of operations.
	The effects of all acquisitions described below were included in the Condensed Consolidated Financial Statements prospectively from the date of acquisition. Unless otherwise indicated, acquisition costs incurred were immaterial and were recorded in administration expense.
	Fiscal 2014 acquisitions
	Aspen Global Inc. – On February 28, 2014, the Company acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global Inc. ("Aspen"). The acquisition of this product portfolio broadened the Company's product offering in Australia and New Zealand and furthered the Company's strategy to expand the Consumer Healthcare portfolio internationally. Operating results attributable to the acquired Aspen products are included in the Consumer Healthcare segment.
	The intangible assets acquired consisted of trademarks and trade names, customer relationships, and non-compete agreements. Customer relationships were assigned a 15-year useful life. Trademarks and trade names were assigned a 25-year useful life and non-compete agreements were assigned a 5-year useful life. The goodwill that was recorded is deductible for tax purposes.
	Fera Pharmaceuticals, LLC – On February 18, 2014, the Company acquired a distribution and license agreement for the marketing and sale of methazolomide from Fera Pharmaceuticals, LLC ("Fera"), a privately-held specialty pharmaceutical company. The acquisition of this agreement further expanded the Company's ophthalmic offerings. Operating results attributable to this agreement are included in the Rx Pharmaceuticals segment. The intangible asset acquired was assigned a 15-year useful life.
	Elan Corporation, plc – On December 18, 2013, the Company acquired Elan in a cash and stock transaction as follows (in millions, except per share data):
	Elan shares outstanding as of December 18, 2013		515.7
	Exchange ratio per share		0.07636
	Total Perrigo shares issued to Elan shareholders		39.4
	Perrigo per share value at transaction close on December 18, 2013		$	155.34
	Total value of Perrigo shares issued to Elan shareholders		6,117.20
	Cash consideration paid at $6.25 per Elan share		3,223.20
	Cash consideration paid for vested Elan stock options and share awards		111.5
	Total consideration		$	9,451.90
	In addition, the Company paid cash consideration of $16.1 million to the Elan stock option and share award holders for the unvested portion of their awards, which was charged to earnings during fiscal 2014.
	At the completion of the transaction, the holder of each Elan ordinary share and each Elan American Depositary Share received from Perrigo $6.25 in cash and 0.07636 of a Perrigo ordinary share. As a result of the transaction, based on the number of outstanding shares of Perrigo and Elan as of December 18, 2013, former Perrigo and Elan shareholders held approximately 71% and 29%, respectively, of Perrigo's ordinary shares immediately after giving effect to the acquisition.
	Elan, headquartered in Dublin, Ireland, provided the Company with assets focused on the treatment of Multiple Sclerosis (Tysabri®). The Company's management believed the acquisition of Elan would provide recurring annual operational synergies, related cost reductions and tax savings. Certain of these synergies resulted from the elimination of redundant public company costs while optimizing back-office support. The jurisdictional mix of income and the new corporate structure have and will continue to result in a lower worldwide effective tax rate.
	The operating results for Elan are included in the Specialty Sciences segment. During fiscal 2014, the Company incurred acquisition-related costs totaling $284.9 million, which were expensed as incurred. These costs were recorded in unallocated expenses and related primarily to general transaction costs (legal, banking and other professional fees), financing fees, and debt extinguishment. See Note 8 for further details on the loss on extinguishment of debt. The table below details these transaction costs and where they were recorded in the Consolidated Statement of Income for fiscal 2014 (in millions).
	Line item		Fiscal 2014
	Administration		$	108.9
	Interest expense, net		10
	Other expense (income), net		0.2
	Loss on extinguishment of debt		165.8
	Total acquisition-related costs		$	284.9
	The Company acquired two definite-lived intangible assets in the acquisition, both of which are exclusive technology agreements:
	Tysabri®: The Company is entitled to royalty payments from Biogen Idec Inc. ("Biogen") based on its Tysabri® revenues in all indications and geographies. The royalty was 12% for the 12-month period ended May 1, 2014. Subsequent to May 1, 2014, the Company is entitled to 18% royalty payments on annual sales up to $2.0 billion and 25% royalty payments on annual sales above $2.0 billion. The asset's value is $5.8 billion, which is being amortized over a useful life of 20 years.
	Prialt: The Company is also entitled to royalty payments based on Prialt revenues. The royalty rates range from 7% to 17.5% based on specific levels of annual U.S. sales. The asset's value is $11.0 million, which is being amortized over a useful life of 10 years.
	Additionally, the Company recorded $2.3 billion of goodwill, which is not deductible for tax purposes, that represents the expected synergies of the combined company, as described above. The following table reflects the allocation by reportable segment (in millions):
	Segment		Goodwill
	Consumer Healthcare		$	1,110.00
	Rx Pharmaceuticals		845.1
	Nutritionals		177.4
	Specialty Sciences		200.6
	Total		$	2,333.10
	Purchase price allocation of fiscal 2014 acquisitions
	The purchase price allocation for Elan was finalized during the first quarter of fiscal 2015. Since June 28, 2014, revisions included a $13.0 million decrease in net tax-related liabilities, resulting in a corresponding decrease in goodwill.
	The below table indicates the purchase price allocation for fiscal 2014 acquisitions (in millions):
		Aspen			Fera		Elan
	Purchase price paid	$	53.7		$	17.3	$	9,451.90
	Contingent consideration	—			0.8		—
	Total purchase consideration	$	53.7		$	18.1	$	9,451.90
	Assets acquired:
	Cash and cash equivalents	$	—		$	—	$	1,807.30
	Investment securities	—			—		100
	Accounts receivable	—			—		44.2
	Inventories	2.7			0.3		—
	Prepaid expenses and other current assets	—			—		27.1
	Property and equipment	—			—		9.2
	Goodwill	4.6			—		2,333.10
	Intangible assets:
	Trade names and trademarks	34.8			—		—
	Customer relationships	9.8			—		—
	Non-competition agreements	1.8			—		—
	Distribution and license agreements	—			17.8		5,811.00
	Intangible assets	46.4			17.8		5,811.00
	Other non-current assets	—			—		93.4
	Total assets	53.7			18.1		10,225.30
	Liabilities assumed:
	Accounts payable	—			—		2
	Accrued liabilities	—			—		120.8
	Deferred tax liabilities	—			—		631.8
Other non-current liabilities	—			—		18.8
Total liabilities	—			—		773.4
Net assets acquired	$	53.7		$	18.1	$	9,451.90
Vedants Drug & Fine Chemicals Private Limited – To further improve the long-term cost position of its API business, on August 6, 2009, the Company acquired an 85% stake in Vedants Drug & Fine Chemicals Private Limited ("Vedants"), an API manufacturing facility in India, for $11.5 million in cash. The Company purchased the remaining 15% stake in Vedants during the second quarter of fiscal 2014 for $7.2 million in cash. The transaction was accounted for as an equity transaction and resulted in the elimination of the noncontrolling interest.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	3 Months Ended
	Sep. 27, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets [Text Block]	'
	GOODWILL AND OTHER INTANGIBLE ASSETS
	Goodwill
	Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
	Reporting Segments:		Balance at June 28, 2014			Business acquisitions			Purchase accounting adjustments				Currency translation adjustment			Balance at September 27, 2014
	Consumer Healthcare		$	1,406.30		$	—		$	(6.2	)		$	(4.6	)	$	1,395.50
	Nutritionals		510.1			—			(1.0		)		—			509.1
	Rx Pharmaceuticals		1,258.30			—			(4.7		)		(12.9		)	1,240.70
	API		97.6			—			—				(6.7		)	90.9
	Specialty Sciences		201.8			—			(1.1		)		—			200.7
	Total goodwill		$	3,474.10		$	—		$	(13.0	)		$	(24.2	)	$	3,436.90
	Intangible assets
	Other intangible assets and related accumulated amortization consisted of the following (in millions):
		September 27, 2014						June 28, 2014
		Gross			Accumulated Amortization			Gross				Accumulated Amortization
	Amortizable intangibles:
	Distribution and license agreements	$	6,026.50		$	269.4		$	6,027.30			$	192.1
	Developed product technology/formulation and product rights	916.9			316.5			931.7				302.5
	Customer relationships	369.2			101.8			372				97.5
	Trade names and trademarks	47.5			5.8			47.8				5.6
	Non-compete agreements	15.1			9.9			15.3				9.4
	Total	$	7,375.20		$	703.4		$	7,394.10			$	607.1
	Non-amortizable intangibles:
	Trade names and trademarks	$	58.4		$	—		$	59.5			$	—
	In-process research and development	7.7			—			10.2				—
	Total	66.1			—			69.7				—
	Total other intangible assets	$	7,441.30		$	703.4		$	7,463.80			$	607.1
	Certain intangible assets are denominated in currencies other than the U.S. dollar; therefore, their gross and net carrying values are subject to foreign currency movements.
	The Company recorded amortization expense of $106.5 million and $29.8 million for the three months ended September 27, 2014 and September 28, 2013, respectively. The increase in amortization expense was due primarily to the incremental amortization expense incurred on the amortizable intangible assets acquired as part of the Elan acquisition.

Inventories_Notes

Inventories (Notes)	3 Months Ended
	Sep. 27, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	INVENTORIES
	Major components of inventory at September 27, 2014 and June 28, 2014, were as follows (in millions):
		September 27,		June 28,
		2014		2014
	Finished goods	$	322.9	$	307
	Work in process	154.3		146.7
	Raw materials	179.6		177.9
	Total inventories	$	656.8	$	631.6

Fair_value_measurements_Note

Fair value measurements (Note)	3 Months Ended
	Sep. 27, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	FAIR VALUE MEASUREMENTS
	Fair value is the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy is used in selecting inputs, with the highest priority given to Level 1, as these are the most transparent or reliable.
	Level 1:	Quoted prices for identical instruments in active markets.
	Level 2:	Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.
	Level 3:	Valuations derived from valuation techniques in which one or more significant inputs are not observable.
	The following tables summarize the valuation of the Company’s financial instruments carried at fair value by the above pricing categories at September 27, 2014 and June 28, 2014 (in millions):
		27-Sep-14
		Level 1			Level 2				Level 3			Total
	Assets:
	Investment securities	$	21.6		$	—			$	—		$	21.6
	Foreign currency forward contracts	—			1.1				—			1.1
	Funds associated with Israeli post employment benefits	—			18.1				—			18.1
	Total assets	$	21.6		$	19.2			$	—		$	40.8
	Liabilities:
	Contingent consideration	$	—		$	—			$	12.4		$	12.4
	Interest rate swap agreements	—			6.9				—			6.9
	Foreign currency forward contracts	—			6.5				—			6.5
	Total liabilities	$	—		$	13.4			$	12.4		$	25.8
		28-Jun-14
		Level 1			Level 2				Level 3			Total
	Assets:
	Investment securities	$	20.7		$	—			$	—		$	20.7
	Foreign currency forward contracts	—			3.1				—			3.1
	Funds associated with Israeli post-employment benefits	—			19.3				—			19.3
	Total assets	$	20.7		$	22.4			$	—		$	43.1
	Liabilities:
	Contingent consideration	$	—		$	—			$	17.4		$	17.4
	Interest rate swap agreements	—			8.3				—			8.3
	Foreign currency forward contracts	—			0.8				—			0.8
	Total liabilities	$	—		$	9.1			$	17.4		$	26.5
	The tables below present a reconciliation for assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended September 27, 2014 and September 28, 2013 (in millions):
		Balance at June 28, 2014		Net realized investment gains (losses) and net change in unrealized appreciation (depreciation) included in net income (loss)			Net change in unrealized appreciation (depreciation) included in other comprehensive income (loss)			Purchases or Additions		Sales		Settlements			Balance at September 27, 2014
	Liabilities:
	Contingent consideration	$	17.4	$	—		$	—		$	—	$	—	$	(5.0	)	$	12.4
		Balance at June 29, 2013		Net realized investment gains (losses) and net change in unrealized appreciation (depreciation) included in net income (loss)			Net change in unrealized appreciation (depreciation) included in other comprehensive income (loss)			Purchases or Additions		Sales		Settlements			Balance at September 28, 2013
	Liabilities:
	Contingent Consideration	$	22.2	$	—		$	—		$	—	$	—	$	—		$	22.2
	Net realized gains (losses) in the tables above were recorded in Other expense (income), net in the Condensed Consolidated Statements of Operations. There were no transfers between Level 1, 2, and 3 during three months ended September 27, 2014 and September 28, 2013. The Company’s policy regarding the recording of transfers between levels is to record any such transfers at the end of the reporting period. See Note 6 for information on the Company's investment securities. See Note 7 for a discussion of derivatives.
	Israeli post-employment benefits represent amounts the Company has deposited in funds managed by financial institutions that are designated by management to cover post-employment benefits for its Israeli employees that are required by Israeli law. The funds are recorded in Other non-current assets on the Condensed Consolidated Balance Sheets and values are determined using prices for recently traded financial instruments with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves, that are observable at commonly quoted intervals.
	Contingent consideration represents milestone payment obligations obtained through product acquisitions and is valued using estimates that utilize probability-weighted outcomes, sensitivity analysis, and discount rates reflective of the risk involved. The estimates are updated quarterly and the liabilities are adjusted to fair value depending on a number of assumptions, including the competitive landscape and regulatory approvals that may impact the future sales of a product.
	As of September 27, 2014 and June 28, 2014, the carrying value and the fair value of the Company’s fixed rate long-term debt was $2.3 billion and $2.4 billion, respectively. As of September 27, 2014 and June 28, 2014, the Company's fixed rate long-term debt consisted of private placement senior notes with registration rights. The fair value was determined by discounting the future cash flows of the financial instruments to their present value, using interest rates currently offered for borrowings and deposits of similar nature and remaining maturities (Level 2).
	The carrying amounts of the Company’s other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt and variable rate long-term debt, approximate their fair value.

Investments_Notes

Investments (Notes)	3 Months Ended
	Sep. 27, 2014
Investments [Abstract]	'
Cost and Equity Method Investments Disclosure [Text Block]	'
	INVESTMENTS
	Available for sale securities
	The Company's available for sale securities totaled $21.6 million at September 27, 2014 and were reported in Investment securities on the Condensed Consolidated Balance Sheets. At June 28, 2014, available for sale securities totaled $20.7 million, of which $5.9 million were reported in Investment securities and $14.8 million were reported in Other non-current assets on the Condensed Consolidated Balance Sheets.
	Net unrealized investment gains (losses) on available for sale securities were as follows (in millions):
		September 27, 2014			June 28,
					2014
	Net unrealized investment gains (losses):
	Equity securities, at cost less impairments	$	17.1		$	17.1
	Gross unrealized gains	4.9			3.8
	Gross unrealized losses	(0.4		)	(0.2		)
	Estimated fair value of equity securities	$	21.6		$	20.7
	The factors affecting the assessment of impairments include both general financial market conditions and factors specific to a particular company. The equity securities in a gross unrealized loss position at September 27, 2014 were in that position for less than 12 months.
	Cost method investments
	The Company's cost method investments totaled $8.7 million and $9.0 million at September 27, 2014 and June 28, 2014, respectively, and are included in Other non-current assets on the Condensed Consolidated Balance Sheets.
	Equity method investments
	The Company's equity method investments totaled $55.6 million and $57.4 million at September 27, 2014 and June 28, 2014, respectively, and are included in Other non-current assets on the Condensed Consolidated Balance Sheets. The Company recorded a net loss of $3.1 million during the three months ended September 27, 2014 related to equity method investments, which is included in Other expense (income), net on the Condensed Consolidated Statements of Operations. No material gains or losses on equity method investments were recorded during the three months ended September 28, 2013.

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Activities (Note)	3 Months Ended
	Sep. 27, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments and Hedging Activities [Text Block]	'
	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
	The Company enters into certain derivative financial instruments, when available on a cost-effective basis, to mitigate its risk associated with changes in interest rates and foreign currency exchange rates as follows:
	Interest rate risk management - The Company is exposed to the impact of interest rate changes. The Company's objective is to manage the impact of interest rate changes on cash flows and the market value of the Company's borrowings. The Company utilizes a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, the Company may enter into treasury-lock agreements ("T-Locks") and interest rate swap agreements on certain investing and borrowing transactions to manage its interest rate changes and to reduce its overall cost of borrowing.
	Foreign currency exchange risk management - The Company conducts business in several major international currencies and is subject to risks associated with changing foreign exchange rates. The Company's objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, the Company enters into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
	All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be largely offset by gains and losses on the original underlying asset or liability. The Company does not use derivative financial instruments for speculative purposes. The notional amount of all derivatives outstanding was $441.0 million and $468.5 million at September 27, 2014 and June 28, 2014, respectively.
	Derivatives instruments designated as hedges
	At September 27, 2014 and June 28, 2014, all of the Company's designated hedging instruments were classified as cash flow hedges. For cash flow hedges that meet hedge accounting criteria, the fair value is recorded in shareholders’ equity as a component of Other comprehensive income ("OCI"), net of tax. These deferred gains and losses are recognized in income in the period in which the hedged item and hedging instrument affect earnings. Any ineffective portion of the change in fair value is immediately recognized in earnings.
	Interest rate swaps
	Interest rate swap agreements are contracts to exchange floating rate for fixed rate payments (or vice versa) over the life of the agreement without the exchange of the underlying notional amounts. The notional amounts of the interest rate swap agreements are used to measure interest to be paid or received and do not represent the amount of exposure to credit loss. The differential paid or received on the interest rate swap agreements is recognized as an adjustment to interest expense.
	During the second quarter of 2014, the Company entered into a $1.0 billion Term Loan Agreement with floating interest rates priced off the LIBOR yield curve, as described in Note 8. The Company had preexisting forward interest rate swap agreements with a notional amount totaling $240.0 million to hedge the change in the LIBOR rate of its previous term loans that were used to hedge the new Term Loan. The after-tax loss for the effective portion of the hedge remains in accumulated other comprehensive income ("AOCI") and continues to be amortized to earnings over the life of the debt.
	During the first quarter of fiscal 2014, the Company entered into forward interest rate swap agreements to hedge against changes in the benchmark interest rate between the date the swap agreements were entered into and the date of the issuance of the Company's new senior notes (discussed collectively in Note 8 as the "Bonds"). These swaps were designated as cash flow hedges of expected future debt issuances with a notional amount totaling $725.0 million. The interest rate swaps were settled upon the issuance of an aggregate of $2.3 billion principal amount on December 18, 2013 for a cumulative after-tax gain of $12.8 million, which was recorded in OCI and is being amortized to earnings over the life of the debt.
	Foreign currency forward contracts
	The Company enters into foreign currency forward contracts in order to hedge the impact of fluctuations of foreign exchange on expected future purchases and related payables denominated in a foreign currency and to hedge the impact of fluctuations of foreign exchange on expected future sales and related receivables denominated in a foreign currency. Both types of forward contracts have a maximum maturity date of 15 months.
	Fair value hedges
	During the first quarter of 2014, the Company entered into three pay-floating interest rate swaps with a total notional amount of $425.0 million to hedge changes in the fair value of the Company's senior notes from fluctuations in interest rates. These swaps were designated and qualified as fair value hedges of the Company's fixed rate debt. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps was directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt were adjusted to market value at the end of each period with any resulting gain or loss recorded in Other expense (income), net. As a result, the Company recorded a net hedge loss of $1.7 million in Other expense (income), net during the three months ended September 28, 2013. Due to the retirement of the underlying senior notes in the second quarter of fiscal year 2014, the hedge was terminated.
	Derivative instruments not designated as hedges
	The Company also has forward foreign currency contracts that are not designated as hedging instruments. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gains or losses on these instruments are substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in Other expense (income), net at the end of each period. The Company recorded losses of $3.3 million and $1.5 million related to these contracts for the three months ended September 27, 2014 and September 28, 2013, respectively.
	The balance sheet location and gross fair value of the Company's derivative instruments at September 27, 2014 and June 28, 2014 were as follows (in millions):
		Asset Derivatives
		Balance Sheet Location		Fair Value
				September 27, 2014				June 28, 2014
	Hedging derivatives:
	Foreign currency forward contracts	Other current assets		$	0.4			$	2.8
	Total hedging derivatives			$	0.4			$	2.8
	Non-hedging derivatives:
	Foreign currency forward contracts	Other current assets		$	0.7			$	0.3
	Total non-hedging derivatives			$	0.7			$	0.3
		Liability Derivatives
		Balance Sheet Location		Fair Value
				September 27, 2014				June 28, 2014
	Hedging derivatives:
	Foreign currency forward contracts	Accrued liabilities		$	4.1			$	0.7
	Interest rate swap agreements	Other non-current liabilities		6.9				8.3
	Total hedging derivatives			$	11			$	9
	Non-hedging derivatives:
	Foreign currency forward contracts	Accrued liabilities		$	2.4			$	0.1
	Total non-hedging derivatives			$	2.4			$	0.1
	The effects (gross of tax) of the Company's cash flow hedges on the Condensed Consolidated Statements of Operations and Condensed Consolidated Statements of Other Comprehensive Income at September 27, 2014 and September 28, 2013 were as follows (in millions):
	Derivatives Qualifying for Cash		Amount of Gain/								Location and Amount of Gain/(Loss)								Location and Amount of Gain/(Loss)
	Flow Hedging		(Loss) Recognized in OCI on Derivative (Effective Portion)								Reclassified from Accumulated OCI into Income								Recognized in Income on Derivative
											(Effective Portion)								(Ineffective Portion and Amount Excluded from Effectiveness Testing)
			September 27, 2014				September 28, 2013						September 27, 2014			September 28, 2013				September 27, 2014		September 28, 2013
	T-Locks		$	—			$	—			Interest expense, net		$	—		$	0.1		Interest expense, net	$	—	$	—
	Interest rate swap agreements		2.7				(15.7		)		Interest expense, net		(0.9		)	(1.3		)	Interest expense, net	—		—
	Foreign currency forward contracts		(5.2		)		2.7				Net sales		0.6			0.7			Net sales	—		—
											Cost of sales		0.4			(1.0		)	Cost of sales	—		(0.4		)
											Interest expense, net		—			0.1
											Other expense (income), net		(0.8		)	1
	Total		$	(2.5	)		$	(13.0	)				$	(0.7	)	$	(0.4	)		$	—	$	(0.4	)
	The effects (gross of tax) of the Company's fair value hedges on the Condensed Consolidated Statements of Operations for three months ended September 28, 2013 were as follows (in millions):
	Fair Value Hedges		Location and Amount of (Gain)/Loss Recognized into Income					Related Hedged Item		Location and Amount of (Gain)/Loss Recognized in Income on Related Hedged Item
				September 28, 2013							September 28, 2013
	Interest rate swap agreements		Other expense (income), net	$	(6.7	)		Fixed-rate debt		Other expense (income), net	$	8.4

Indebtedness_note

Indebtedness (note)	3 Months Ended
	Sep. 27, 2014
Aggregate Indebtedness [Abstract]	'
Indebtedness [Text Block]	'
	INDEBTEDNESS
	Debt
	Total borrowings outstanding are summarized as follows (in millions):
		September 27,			June 28,
		2014			2014
	Short term debt	$	—		$	2.1
	Term loans
	2013 Term Loan due December 15, 2015	300			300
	2013 Term Loan due December 15, 2018	595			630
		895			930
	Senior notes
	1.30% Unsecured Senior Notes due November 8, 2016, including unamortized discount of $0.4 million(1)	499.6			499.6
	2.30% Unsecured Senior Notes due November 8, 2018, including unamortized discount of $0.7 million(1)	599.3			599.3
	4.00% Unsecured Senior Notes due November 15, 2023, including unamortized discount of $3.1 million(1)	796.8			796.8
	5.30% Unsecured Senior Notes due November 15, 2043, including unamortized discount of $1.7 million(1)	398.3			398.3
		2,294.00			2,294.00
	Other financing	3.3			8.1
	Total borrowings outstanding	3,192.30			3,234.20
	Less short-term debt and current portion of long-term debt	(141.5		)	(143.7		)
	Total long-term debt, less current portion	$	3,050.80		$	3,090.50
	(1) Private placement unsecured senior notes with registration rights discussed below collectively as the "Bonds."
	Unamortized deferred financing fees totaled $26.2 million at September 27, 2014 and $27.4 million at June 28, 2014. The Company was in compliance with all covenants under its various debt agreements at September 27, 2014.
	Bridge agreements
	In connection with the Elan acquisition described in Note 2, on July 28, 2013, the Company entered into a $2.65 billion Debt Bridge Credit Agreement (the "Debt Bridge") and a $1.7 billion Cash Bridge Credit Agreement (the "Cash Bridge") with HSBC Bank USA, N.A. as Syndication Agent, Barclays Bank PLC as Administrative Agent and certain other participant banks (together, the "Bridge Credit Agreements"). The funding commitment under the Debt Bridge was reduced by $1.0 billion on September 6, 2013 upon completion of the Company’s Term Loan Agreement (see below) and by an additional $1.65 billion on November 8, 2013 upon funding into escrow of the Company’s public bond offering (see below), at which time the Debt Bridge was terminated. The commitments under the Cash Bridge were terminated on December 24, 2013. At no time did the Company draw under the Bridge Credit Agreements.
	Debt extinguishment
	On December 18, 2013, the Company repaid the remaining principal balance with accrued interest and fees of $360.0 million, then outstanding under its credit agreement dated as of October 26, 2011 with JPMorgan Chase Bank, N.A., as Administrative Agent, Bank of America, N.A. and Morgan Stanley Senior Funding, Inc., as Syndication Agents and certain other participant banks (the "2011 Credit Agreement"). Upon completion of such payment, the 2011 Credit Agreement was terminated in its entirety.
	On November 20, 2013, the Company priced a Tender Offer and Consent Solicitation in regard to the 2.95% Notes which were issued pursuant to the Indenture dated as of May 16, 2013 between the Company and Wells Fargo Bank, National Association (the "Indenture"). The total tender consideration was $578.3 million. On December 26, 2013, pursuant to the Indenture, notice was given to holders that the remaining notes not duly tendered would be redeemed on December 27, 2013 at a redemption price of par plus accrued interest. On December 27, 2013, the redemption was completed for a total payment of $28.5 million. Upon completion of the redemption, the Indenture was terminated.
	On December 23, 2013, the Company completed the prepayment of all obligations under its private placement senior notes (the "Notes"). All of the Notes were outstanding under the Master Note Purchase Agreement dated May 29, 2008 with various institutional investors (the "Note Agreement"). The terms of the Note Agreement provided for prepayment at any time at the Company's option together with applicable make-whole premiums and accrued interest, which totaled $1,099.6 million. Upon completion of the prepayment, the Note Agreement was terminated.
	As a result of the debt retirements, the Company recorded a loss of $165.8 million during the second quarter of fiscal 2014 as follows (in millions):
	Make-whole payments		$	133.5
	Write-off of financing fees on Bridge Credit Agreements		19
	Write-off of deferred financing fees		10.5
	Write-off of unamortized discount		2.8
	Total loss on extinguishment of debt		$	165.8
	Debt issuance
	On September 6, 2013, the Company entered into a $1.0 billion Term Loan Agreement (the "Term Loan") and a $600.0 million Revolving Credit Agreement (the "Revolver") with Barclays Bank PLC as Administrative Agent, HSBC Bank USA, N.A. as Syndication Agent, Bank of America, N.A., JPMorgan Chase Bank, N.A. and Wells Fargo Bank, N.A. as Documentation Agents and certain other participant banks (together, the "Permanent Credit Agreements"). The Term Loan consists of a $300.0 million tranche maturing December 18, 2015 and a $700.0 million tranche maturing December 18, 2018. Both tranches were drawn in full on December 18, 2013. No amounts were outstanding under the Revolver as of September 27, 2014 or June 28, 2014.
	Obligations of the Company under the Permanent Credit Agreements are guaranteed by the Company, certain U.S. subsidiaries of the Company, Elan, and certain Irish subsidiaries of Elan. Amounts outstanding under each of the Permanent Credit Agreements will bear interest at the Company’s option (a) at the alternative base rate or (b) the eurodollar rate plus, in either case, applicable margins as set forth in the Permanent Credit Agreements.
	On November 8, 2013, the Company issued $500.0 million aggregate principal amount of its 1.30% Senior Notes due 2016 (the "2016 Notes"), $600.0 million aggregate principal amount of its 2.30% Senior Notes due 2018 (the "2018 Notes"), $800.0 million aggregate principal amount of its 4.00% Senior Notes due 2023 (the "2023 Notes") and $400.0 million aggregate principal amount of its 5.30% Senior Notes due 2043 (the "2043 Notes" and, together with the 2016 Notes, the 2018 Notes and the 2023 Notes, the "Bonds") in a private placement with registration rights. Interest on the Bonds is payable semiannually in arrears in May and November of each year, beginning in May 2014. The Bonds are governed by a Base Indenture and a First Supplemental Indenture between the Company and Wells Fargo Bank N.A., as trustee (collectively the "2013 Indenture"). The Bonds are the Company’s unsecured and unsubordinated obligations, ranking equally in right of payment to all of the Company’s existing and future unsecured and unsubordinated indebtedness and are guaranteed on an unsubordinated, unsecured basis by the Company's subsidiaries that guarantee the Permanent Credit Agreements. The Company received net proceeds of $2.3 billion from issuance of the Bonds after fees and market discount. The Bonds are not entitled to mandatory redemption or sinking fund payments. The Company may redeem the Bonds in whole or in part at any time and from time to time for cash at the redemption prices described in the 2013 Indenture.
	On September 2, 2014, the Company offered to exchange its private placement senior notes with public bonds (the "Exchange Offer"). The Exchange Offer expired on October 1, 2014, at which time a substantial majority of the private placement notes had been exchanged for bonds registered with the Securities and Exchange Commission.
	Accounts receivable securitization
	The Company has a one year accounts receivable securitization program with Wells Fargo Bank, National Association ("Wells Fargo") as sole agent, which was renewed on June 13, 2014. Under the terms of the securitization program, the subsidiaries sell certain eligible trade accounts receivables to a wholly owned bankruptcy-remote special purpose entity ("SPE"), Perrigo Receivables, LLC. The Company has retained servicing responsibility for those receivables. The SPE will then transfer an interest in the receivables to the Committed Investors. Under the terms of the securitization program, Wells Fargo has committed $200.0 million, effectively allowing the Company to borrow up to that amount, subject to a maximum net investment calculation as defined in the agreement. At September 27, 2014, the entire $200.0 million committed amount of the securitization program was available under this calculation. The annual interest rate on any borrowing is equal to thirty-day LIBOR plus 0.375%. In addition, an annual facility fee of 0.375% is applied to the entire $200.0 million commitment whether borrowed or undrawn. Under the terms of the securitization program, the Company may elect to have the entire amount or any portion of the facility unutilized. There were no borrowings outstanding under the securitization program at September 27, 2014 or June 28, 2014.

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Sep. 27, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY
	Earnings per share
	A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):
		Three Months Ended
		September 27,		September 28,
		2014		2013
	Numerator:
	Net income	$	96.3	$	111.4
	Denominator:
	Weighted average shares outstanding for basic EPS	133.9		94.2
	Dilutive effect of share-based awards	0.5		0.5
	Weighted average shares outstanding for diluted EPS	134.4		94.7
	Anti-dilutive share-based awards excluded from computation of diluted EPS	0.1		0.1
	Shareholders' equity
	Perrigo Company plc (formerly known as Perrigo Company Limited, and prior thereto, Blisfont Limited) was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant to Perrigo Company on December 18, 2013 in connection with the consummation of the acquisition of Elan. Perrigo Company shares were canceled and exchanged for Perrigo Company plc shares on a one-for-one basis (together with the payment of $0.01 in cash per Perrigo Company share). All the remaining unsold shares of Perrigo Company were deregistered. Perrigo Company plc began trading on the New York Stock Exchange on December 19, 2013 and the Tel Aviv Stock Exchange on December 22, 2013 under the same symbol used by Perrigo Company ("PRGO") prior to December 18, 2013. See Note 2 for additional information about the acquisition of Elan.
	The Company issued 186 thousand and 264 thousand shares related to the exercise and vesting of share-based compensation during the three months ended September 27, 2014 and September 28, 2013, respectively.
	The Company does not currently have an ordinary share repurchase program.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income	3 Months Ended
	Sep. 27, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	ACCUMULATED OTHER COMPREHENSIVE INCOME
	Changes in the Company's AOCI balances, net of tax, for the three months ended September 27, 2014 were as follows (in millions):
		Foreign			Fair value			Fair value of		Post-			Total AOCI
		currency			of derivative			investment		retirement and pension
		translation			financial			securities,		liability
		adjustments			instruments,			net of tax		adjustments,
					net of tax					net of tax
	Balance at June 28, 2014	$	164.4		$	(16.1	)	$	2.4	$	(11.1	)	$	139.6
	OCI before reclassifications	(63.8		)	(1.7		)	0.6		—			(64.9		)
	Amounts reclassified from AOCI	—			(0.4		)	—		—			(0.4		)
	Other comprehensive income	(63.8		)	(2.1		)	0.6		—			(65.3		)
	Balance at September 27, 2014	$	100.6		$	(18.2	)	$	3	$	(11.1	)	$	74.3

Income_Taxes

Income Taxes	3 Months Ended
	Sep. 27, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	– INCOME TAXES
	The effective tax rate for the three months ended September 27, 2014 was 11.4% compared to 29.2% for the three months ended September 28, 2013. The effective tax rate for the three months ended September 27, 2014 was impacted by changes to the estimated jurisdictional mix of income and the new corporate structure attributable to the acquisition of Elan. Additionally, the effective tax rate for the three months ended September 28, 2013 was unfavorably impacted by Israel tax rate changes in the amount of $1.8 million and favorably impacted by United Kingdom tax rate changes in the amount of $4.7 million as discussed further below.
	In fiscal 2011, Israel enacted new tax legislation that reduced the effective tax rate to 10% for 2011 and 2012, 7% for 2013 and 2014, and 6% thereafter for certain qualifying entities that elect to be taxed under the new legislation. This legislation was rescinded as announced in the Official Gazette on August 5, 2013. The new legislation enacted a 9% rate for certain qualifying entities that elect to be taxed under the new legislation. The Company has two entities that had previously elected the new tax legislation for years after fiscal 2011. For all other entities that do not qualify for this reduced rate, the tax rate has been increased from 25% to 26.5%. These rates were applicable to Perrigo as of the first quarter of fiscal 2014 and unfavorably impacted the effective tax rate in the amount of $1.8 million.
	In July 2013, the United Kingdom passed legislation reducing the statutory rate to 21% and 20% effective April 1, 2014 and April 1, 2015, respectively. These rates were applicable to Perrigo as of the first quarter of fiscal 2014 and favorably impacted the effective tax rate in the amount of $4.7 million.
	In December 2013, Mexico enacted legislation to rescind the scheduled rate reductions and maintain the 30% corporate tax rate for 2014 and future years. This rate was applicable to Perrigo as of June 30, 2013.
	The Company's tax rate is subject to adjustment over the balance of the fiscal year due to, among other things, income tax rate changes by governments; the jurisdictions in which the Company's profits are determined to be earned and taxed, and the relative amounts of income in these jurisdictions; changes in the valuation of the Company's deferred tax assets and liabilities; adjustments to estimated taxes upon finalization of various tax returns; the resolution of any pending or future tax audit, examination or challenge; adjustments to the Company's interpretation of transfer pricing standards, changes in available tax credits, grants and other incentives; changes in stock-based compensation expense; changes in tax laws or the interpretation of such tax laws (for example, proposals for fundamental U.S. international tax reform); changes in U.S. generally accepted accounting principles; expiration or the inability to renew tax rulings or tax holiday incentives; and the repatriation of earnings with respect to which the Company has not previously provided for taxes.
	The total liability for uncertain tax positions was $291.5 million and $205.4 million as of September 27, 2014 and June 28, 2014, respectively, before considering the federal tax benefit of certain state and local items. This increase is primarily due to the adoption of ASU 2013-11 concerning the offset of applicable deferred tax assets for net operating loss, tax credit or other similar carryforwards. See Note 1 for additional information regarding the adoption.
	The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. The total amount accrued for interest and penalties in the liability for uncertain tax positions was $42.3 million and $45.3 million as of September 27, 2014 and June 28, 2014, respectively.
	The Company’s primary income tax jurisdictions are Ireland, the U.S. and Israel.  Because the Company files income tax returns in Ireland, the U.S. (including various state and local jurisdictions), Israel and numerous other jurisdictions, it is subject to audits by tax authorities from several jurisdictions.
	Although we believe that our tax estimates are reasonable and that we prepare our tax filings in accordance with all applicable tax laws, the final determination with respect to any tax audit, and any related litigation, could be materially different from our estimates or from our historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on operating results or cash flows in the periods for which that determination is made. In addition, future period earnings may be adversely impacted by litigation costs, settlements, penalties, or interest assessments.
	Currently, the IRS is auditing fiscal years 2009 and 2010, and the Israel Tax Authority is auditing fiscal years 2011 and 2012. In regards to the IRS audit for fiscal years 2009 and 2010, the Company has agreed on certain adjustments and has made associated payments of $8.0 million, inclusive of interest, but remains under audit for those years. On August 27, 2014, the Company received a statutory notice of deficiency from the IRS related to fiscal years 2009 and 2010. The incremental tax liability asserted by the IRS for these periods is approximately $43.0 million, exclusive of interest and penalties. The IRS has asserted various positions, including transfer pricing. As the Company disagrees with positions asserted by the IRS, it intends to contest the IRS’s positions through applicable procedures in either the U.S. Tax Court or U.S. Federal court, the latter of which would require the Company to pay the asserted liability, plus interest and penalties, prior to initiating any refund litigation. The unfavorable resolution of this matter could have a material impact on the Company's consolidated financial statements in future periods. There are numerous other income tax jurisdictions for which tax returns are not yet settled, none of which are individually significant. At this time, the Company cannot predict the outcome of any audit or related litigation.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 27, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies [Text Block]	'
	COMMITMENTS AND CONTINGENCIES
	In addition to the discussions below, the Company has pending certain other legal actions and claims incurred in the normal course of business. The Company records accruals for such contingencies when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of September 27, 2014, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals for new information and further development. Other than the items disclosed below, the Company considers the remainder of litigation matters to be immaterial individually and in the aggregate.
	Texas Medicaid
	In June 2013, the Company received notices from the Office of the Attorney General for the State of Texas, of civil investigative demands to two of the Company’s affiliates, Perrigo Pharmaceuticals Company and Paddock Laboratories, LLC, for information under the Texas Medicaid Fraud Prevention Act relating to the submission of prices to Texas Medicaid in claims for reimbursement for drugs. The Company has cooperated with requests for information and is in the process of evaluating this and other information. While the Company does not know the full extent of its potential liability at this time and intends to vigorously defend against any claims, the Company could be subject to material penalties and damages. The Company has established a contingency loss accrual of $15.0 million to cover potential settlement or other outcomes. The Company cannot predict whether settlement on terms acceptable to it will occur, or that a settlement or potential liability for these claims will not be higher than the amount recorded.
	Eltroxin
	During October and November 2011, nine applications to certify a class action lawsuit were filed in various courts in Israel related to Eltroxin, a prescription thyroid medication manufactured by a third party and distributed in Israel by Perrigo Israel Agencies Ltd. The respondents include Perrigo Israel Pharmaceuticals Ltd. and/or Perrigo Israel Agencies Ltd., the manufacturers of the product, and various health care providers who provide health care services as part of the compulsory health care system in Israel.
	The nine applications arose from the 2011 launch of a reformulated version of Eltroxin in Israel. The applications generally alleged that the respondents (a) failed to timely inform patients, pharmacists and physicians about the change in the formulation; and (b) failed to inform physicians about the need to monitor patients taking the new formulation in order to confirm patients were receiving the appropriate dose of the drug. As a result, claimants allege they incurred the following damages: (a) purchases of product that otherwise would not have been made by patients had they been aware of the reformulation; (b) adverse events to some patients resulting from an imbalance of thyroid functions that could have been avoided; and (c) harm resulting from the patients' lack of informed consent prior to the use of the reformulation.
	All nine applications were transferred to one court in order to determine whether to consolidate any of the nine applications. On July 19, 2012, the court dismissed one of the applications and ordered that the remaining eight applications be consolidated into one application. On September 19, 2012, a consolidated motion to certify the eight individual motions was filed by lead counsel for the claimants. Generally, the allegations in the consolidated motion are the same as those set forth in the individual motions; however, the consolidated motion excluded the manufacturer of the reformulated Eltroxin as a respondent. Several hearings on whether or not to certify the consolidated application took place in December 2013 and January 2014. As this matter is in its early stages, the Company cannot reasonably predict at this time the outcome or the liability, if any, associated with these claims.
	Neot Hovav
	In March and June of 2007, lawsuits were filed by three separate groups against both the State of Israel and the Council of Neot Hovav in connection with waste disposal and pollution from several companies, including the Company, that have operations in the Neot Hovav region of Israel. These lawsuits were subsequently consolidated into a single proceeding in the District Court of Beer-Sheva.  The Council of Neot Hovav, in June 2008, and the State of Israel, in November 2008, asserted third-party claims against several companies, including the Company.  The pleadings allege a variety of personal injuries arising out of the alleged environmental pollution.  Neither the plaintiffs nor the third-party claimants were required to specify a maximum amount of damages, but the pleadings allege damages in excess of $72.5 million, subject to foreign currency fluctuations between the Israeli shekel and the U.S. dollar.  On January 9, 2013, the District Court of Beer-Sheva ruled in favor of the Company.  On September 29, 2014, the Supreme Court of Israel affirmed the ruling of the District Court in favor of the Company and as a result, the matter is now closed.
	Tysabri® product liability lawsuits
	The Company and collaborator Biogen are co-defendants in product liability lawsuits arising out of the occurrence of Progressive Multifocal Leukoencephalopathy ("PML"), a serious brain infection, and serious adverse events, including deaths, which occurred in patients taking Tysabri®. The Company and Biogen will each be responsible for 50% of losses and expenses arising out of any Tysabri® product liability claims. While these lawsuits will be vigorously defended, management cannot predict how these cases will be resolved. Adverse results in one or more of these lawsuits could result in substantial judgments against the Company.

Restructuring

Restructuring	3 Months Ended
	Sep. 27, 2014
Restructuring Charges [Abstract]	'
Restructuring [Text Block]	'
	RESTRUCTURING CHARGES
	The Company periodically takes actions to reduce redundant expenses and improve operating efficiencies, typically in connection with its business acquisitions. The following summarizes the Company's restructuring activity for the three months ended September 27, 2014 and September 28, 2013 (in millions):
		Three Months Ended
		27-Sep-14			28-Sep-13
	Beginning balance	$	16.4		$	2.9
	Additional charges	1.7			2.1
	Payments	(13.5		)	(1.4		)
	Non-cash adjustments	(0.7		)	—
	Ending balance	$	3.9		$	3.6
	Restructuring activity includes severance, lease exit, and asset impairments. Charges are shown in Restructuring on the Company's Condensed Consolidated Statements of Operations. Substantially all of the remaining liability for employee severance benefits and lease exit costs will be paid within the fiscal year.

Segment_Information

Segment Information	3 Months Ended
	Sep. 27, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	SEGMENT INFORMATION
	The Company has five reportable segments, aligned primarily by type of product: Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, and Specialty Sciences, along with an Other category. In conjunction with the acquisition of Elan on December 18, 2013, the Company expanded its operating segments to include the Specialty Sciences segment, which is comprised of assets focused on the treatment of Multiple Sclerosis (Tysabri®). The majority of corporate expenses, which generally represent shared services, are charged to operating segments as part of a corporate allocation. Unallocated expenses relate to certain corporate services that are not allocated to the segments.
		Three Months Ended
		27-Sep-14
		Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
	Consumer Healthcare	$	493.3	$	65.3		$	8.6	$	3,828.00
	Nutritionals	125.3		8.6			7.2		1,072.60
	Rx Pharmaceuticals	194.5		64.7			17		2,509.10
	API	24.8		7.1			0.5		251.2
	Specialty Sciences	91.9		14.9			72.8		6,023.00
	Other	21.7		0.9			0.4		97.1
	Unallocated expenses	—		(24.3		)	—		—
	Total	$	951.5	$	137.2		$	106.5	$	13,781.00
		Three Months Ended
		28-Sep-13
		Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
	Consumer Healthcare	$	538.5	$	89.9		$	5.3	$	2,508.60
	Nutritionals	129		7.7			7.4		930.7
	Rx Pharmaceuticals	203.6		83.1			16.2		1,669.00
	API	43.2		22.4			0.5		295.2
	Specialty Sciences	—		—			—		—
	Other	19.1		1.2			0.4		105.3
	Unallocated expenses	—		(24.6		)	—		—
	Total	$	933.4	$	179.7		$	29.8	$	5,508.80

Guarantor_Financials_Notes

Guarantor Financials (Notes)	3 Months Ended
	Sep. 27, 2014
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
Condensed Financial Information of Parent Company Only Disclosure [Text Block]	'
	– GUARANTOR CONDENSED CONSOLIDATING FINANCIAL STATEMENTS
	The Company and certain other of its principal 100% owned subsidiaries (the "Guarantors") fully and unconditionally guaranteed, on a joint and several basis, the Bonds. The following tables present condensed consolidated financial information for (a) the Company (for purposes of this discussion and table, "Parent"); (b) the guarantors of the Bonds, which include substantially all of the U.S., 100% owned subsidiaries of the Parent and specific Elan subsidiaries ("Subsidiary Guarantors"); and (c) the wholly- and partially-owned non-U.S. subsidiaries of the Parent, which do not guarantee the Notes ("Non-Guarantor Subsidiaries"). Separate financial statements of the Subsidiary Guarantors are not presented because they are fully and unconditionally, jointly and severally liable under the guarantees. The consolidating adjustments primarily relate to eliminations of investments in subsidiaries and intercompany balances and transactions. The condensed consolidating financial statements present investments in subsidiaries using the equity method of accounting.
	Perrigo Company plc, which was formed on December 18, 2013, is the Parent Company. For periods prior to December 18, 2013, the Parent entity is Perrigo Company, which is a guarantor, therefore no Parent column is presented for the three months ended September 28, 2013.
	CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Three Months Ended September 27, 2014
	(in millions)
		Unconsolidated
		Perrigo Company plc			Guarantor Subsidiaries			Non-Guarantor Subsidiaries				Eliminating Entries				Consolidated
	Net sales	$	—		$	829.7		$	263.7			$	(141.9	)		$	951.5
	Cost of sales	—			582.1			169.2				(121.6		)		629.7
	Gross profit	—			247.6			94.5				(20.3		)		321.8
	Operating expenses
	Distribution	—			11			3.4				—				14.4
	Research and development	—			21.7			14.9				—				36.6
	Selling	—			39.8			10.6				—				50.4
	Administration	13.7			51.1			17.2				(0.5		)		81.5
	Restructuring	—			1.7			—				—				1.7
	Total operating expenses	13.7			125.3			46.1				(0.5		)		184.6
	Operating income (loss)	(13.7		)	122.3			48.4				(19.8		)		137.2
	Interest expense, net	23.9			192.6			(190.5		)		(0.1		)		25.9
	Other expense (income), net	—			(1.8		)	3.8				0.7				2.7
	Income (loss) before income taxes and equity in net income (loss) of subsidiaries	(37.6		)	(68.5		)	235.1				(20.4		)		108.6
	Income tax expense	(1.6		)	3.6			10.3				—				12.3
	Income (loss) before equity in net income (loss) of subsidiaries	(36.0		)	(72.1		)	224.8				(20.4		)		96.3
	Equity in net income (loss) of subsidiaries	132.3			54.6			35.8				(222.7		)		—
	Net income (loss)	$	96.3		$	(17.5	)	$	260.6			$	(243.1	)		$	96.3
	CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)
	For the Three Months Ended September 27, 2014
	(in millions)
		Unconsolidated
		Perrigo Company plc			Guarantor Subsidiaries			Non-Guarantor Subsidiaries				Eliminating Entries				Consolidated
	Net income (loss)	$	96.3		$	(17.5	)	$	260.6			$	(243.1	)		$	96.3
	Other comprehensive income (loss):
	Foreign currency translation adjustments	(63.8		)	(0.2		)	(63.6		)		63.8				(63.8		)
	Change in fair value of derivative financial instruments, net of tax	(2.1		)	0.9			(0.5		)		(0.4		)		(2.1		)
	Change in fair value of investment securities, net of tax	0.6			(1.3		)	3				(1.7		)		0.6
	Change in post-retirement and pension liability adjustments, net of tax	—			—			—				—				—
	Other comprehensive income (loss), net of tax	(65.3		)	(0.6		)	(61.1		)		61.7				(65.3		)
	Comprehensive income (loss)	$	31		$	(18.1	)	$	199.5			$	(181.4	)		$	31
	CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Three Months Ended September 28, 2013
	(in millions)
		Unconsolidated
		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminating Entries				Consolidated
	Net sales	$	802.1		$	276.4		$	(145.1	)		$	933.4
	Cost of sales	537			168.2			(128.1		)		577.1
	Gross profit	265.1			108.2			(17.0		)		356.3
	Operating expenses
	Distribution	10.6			2.6			—				13.2
	Research and development	21.8			10.5			—				32.3
	Selling	39.8			10.4			—				50.2
	Administration	71			7.8			—				78.8
	Restructuring	2.1			—			—				2.1
	Total operating expenses	145.3			31.3			—				176.6
	Operating income (loss)	119.8			76.9			(17.0		)		179.7
	Interest expense, net	20.1			1.3			—				21.4
	Other expense (income), net	0.9			0.1			—				1
	Income (loss) before income taxes and equity in net income (loss) of subsidiaries	98.8			75.5			(17.0		)		157.3
	Income tax expense	42.2			3.7			—				45.9
	Income (loss) before equity in net income (loss) of subsidiaries	56.6			71.8			(17.0		)		111.4
	Equity in net income (loss) of subsidiaries	54.8			30.8			(85.6		)		—
	Net income (loss)	$	111.4		$	102.6		$	(102.6	)		$	111.4
	CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME
For the Three Months Ended September 28, 2013
(in millions)
	Unconsolidated
	Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminating Entries				Consolidated
Net income	$	111.4		$	102.6		$	(102.6	)		$	111.4
Other comprehensive income (loss):
Foreign currency translation adjustments	36.6			37.2			(37.2		)		36.6
Change in fair value of derivative financial instruments, net of tax	(9.2		)	0.3			(0.3		)		(9.2		)
Change in fair value of investment securities, net of tax	—			—			—				—
Change in post-retirement and pension liability adjustments, net of tax	(0.1		)	—			—				(0.1		)
Other comprehensive income (loss), net of tax	27.3			37.5			(37.5		)		27.3
Comprehensive income	$	138.7		$	140.1		$	(140.1	)		$	138.7
CONDENSED CONSOLIDATING BALANCE SHEET
September 27, 2014
(in millions)
	Unconsolidated
	Perrigo Company plc			Guarantor Subsidiaries			Non-Guarantor Subsidiaries				Eliminating Entries				Consolidated
Assets
Cash and cash equivalents	$	424.7		$	233.6		$	233.2			$	—			$	891.5
Investment securities	—			16.5			5.1				—				21.6
Accounts receivable, net	2			283			1,822.60				(1,238.2		)		869.4
Inventories	—			658.4			148.1				(149.7		)		656.8
Current deferred income taxes	—			61.3			3.3				—				64.6
Prepaid expenses and other current assets	20.6			60.1			49.4				—				130.1
Total current assets	447.3			1,312.90			2,261.70				(1,387.9		)		2,634.00
Property and equipment, net	—			526.4			235.3				—				761.7
Goodwill and other indefinite-lived intangible assets	—			3,065.30			437.7				—				3,503.00
Other intangible assets, net	—			6,475.40			196.4				—				6,671.80
Non-current deferred income taxes	14.4			10.9			3.2				—				28.5
Other non-current assets	23			74.5			84.5				—				182
Intercompany loans receivable	7,300.00			2,065.70			14,242.30				(23,608.0		)		—
Investments in subsidiaries	6,284.90			8,538.30			367.5				(15,190.7		)		—
Total non-current assets	13,622.30			20,756.50			15,566.90				(38,798.7		)		11,147.00
Total assets	$	14,069.60		$	22,069.40		$	17,828.60			$	(40,186.6	)		$	13,781.00
Liabilities and Shareholders’ Equity
Accounts payable	$	40.4		$	1,254.00		$	252.2			$	(1,237.6	)		$	309
Payroll and related taxes	0.1			56.2			20.7				—				77
Accrued customer programs	—			35			239.5				—				274.5
Accrued liabilities	32.5			102.2			45.6				(0.4		)		179.9
Accrued income taxes	(0.6		)	12.7			19.6				—				31.7
Current deferred income taxes	—			4.3			—				—				4.3
Current portion of long-term debt	140			1.5			—				—				141.5
Total current liabilities	212.4			1,465.90			577.6				(1,238.0		)		1,017.90
Long-term debt, less current portion	3,049.20			1.6			—				—				3,050.80
Non-current deferred income taxes	—			692.2			16.5				—				708.7
Other non-current liabilities	—			192.4			94.5				—				286.9
Intercompany loans payable	2,091.30			13,849.00			7,667.70				(23,608.0		)		—
Total non-current liabilities	5,140.50			14,735.20			7,778.70				(23,608.0		)		4,046.40
Total liabilities	5,352.90			16,201.10			8,356.30				(24,846.0		)		5,064.30
Shareholders’ equity	8,716.70			5,868.30			9,472.30				(15,340.6		)		8,716.70
Total liabilities and shareholders' equity	$	14,069.60		$	22,069.40		$	17,828.60			$	(40,186.6	)		$	13,781.00
CONDENSED CONSOLIDATING BALANCE SHEET
June 28, 2014
(in millions)
	Unconsolidated
	Perrigo Company plc			Guarantor Subsidiaries			Non-Guarantor Subsidiaries				Eliminating Entries				Consolidated
Assets
Cash and cash equivalents	$	323.4		$	245.2		$	230.9			$	—			$	799.5
Investment securities	—			—			5.9				—				5.9
Accounts receivable, net	1.4			463.9			4,495.70				(4,025.9		)		935.1
Inventories	—			613.9			148.1				(130.4		)		631.6
Current deferred income taxes	—			59.8			3				—				62.8
Prepaid expenses and other current assets	9.9			62.7			43.4				—				116
Total current assets	334.7			1,445.50			4,927.00				(4,156.3		)		2,550.90
Property and equipment, net	—			532.4			247.5				—				779.9
Goodwill and other indefinite-lived intangible assets	—			3,078.30			465.5				—				3,543.80
Other intangible assets, net	—			6,583.80			203.2				—				6,787.00
Non-current deferred income taxes	16			—			23.6				(16.0		)		23.6
Other non-current assets	23.8			84.5			86.7				—				195
Intercompany loans receivable	7,300.00			2,145.70			11,444.10				(20,889.8		)		—
Investments in subsidiaries	6,218.90			7,826.90			325.2				(14,371.0		)		—
Total non-current assets	13,558.70			20,251.60			12,795.80				(35,276.8		)		11,329.30
Total assets	$	13,893.40		$	21,697.10		$	17,722.80			$	(39,433.1	)		$	13,880.20
Liabilities and Shareholders’ Equity
Accounts payable	$	35.2		$	3,998.00		$	487.3			$	(4,156.2	)		$	364.3
Short-term debt	—			—			2.1				—				2.1
Payroll and related taxes	0.1			79.9			32.3				—				112.3
Accrued customer programs	—			65.6			190.9				—				256.5
Accrued liabilities	11.4			121.8			46.7				(0.5		)		179.4
Accrued income taxes	—			3.4			14				—				17.4
Current deferred income taxes	—			1.1			—				—				1.1
Current portion of long-term debt	140			1.6			—				—				141.6
Total current liabilities	186.7			4,271.40			773.3				(4,156.7		)		1,074.70
Long-term debt, less current portion	3,084.00			1.9			4.6				—				3,090.50
Non-current deferred income taxes	—			709.6			34.3				(16.0		)		727.9
Other non-current liabilities	—			182.6			110.8				—				293.4
Intercompany loans payable	1,929.00			11,291.50			7,667.80				(20,888.3		)		—
Total non-current liabilities	5,013.00			12,185.60			7,817.50				(20,904.3		)		4,111.80
Total liabilities	5,199.70			16,457.00			8,590.80				(25,061.0		)		5,186.50
Controlling interest	8,693.70			5,240.10			9,131.20				(14,372.1		)		8,692.90
Non-controlling interest	—			—			0.8				—				0.8
Shareholders’ equity	8,693.70			5,240.10			9,132.00				(14,372.1		)		8,693.70
Total liabilities and shareholders' equity	$	13,893.40		$	21,697.10		$	17,722.80			$	(39,433.1	)		$	13,880.20
CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS
For the Three Months Ended September 27, 2014
(in millions)
	Unconsolidated
	Perrigo Company plc			Guarantor Subsidiaries			Non-Guarantor Subsidiaries					Eliminating Entries				Consolidated
Net cash from (for) operating activities	$	(91.2	)	$	211.3		$	75		—		$	—			$	195.1
Cash Flows From (For) Investing Activities
Additions to property and equipment	—			(18.4		)	(13.3		)			—				(31.7		)
(Purchase) return of investment	—			1.2			(1.3		)			—				(0.1		)
Proceeds from sale of business	—			—			1.1					—				1.1
Intercompany notes issued	—			(202.1		)	(243.6		)			445.7				—
Net cash from (for) investing activities	—			(219.3		)	(257.1		)			445.7				(30.7		)
Cash Flows From (For) Financing Activities																—
Repayments of long-term debt	(35.0		)	—			(4.5		)			—				(39.5		)
Cash dividends	(14.1		)	—			—					—				(14.1		)
Repurchase of common stock	(7.5		)	—			—					—				(7.5		)
Settlements of contingent consideration	—			(5.0		)	—					—				(5.0		)
Borrowings (repayments) of short-term debt, net	—			—			(2.1		)			—				(2.1		)
Issuance of common stock	2.6			—			—					—				2.6
Excess tax benefit of stock transactions	4.3			—			—					—				4.3
Intercompany notes borrowed	242.2			1.4			202.1					(445.7		)		—
Net cash from (for) financing activities	192.5			(3.6		)	195.5					(445.7		)		(61.3		)
Effect of exchange rate changes on cash	—			—			(11.1		)			—				(11.1		)
Net increase (decrease) in cash and cash equivalents	101.3			(11.6		)	2.3					—				92
Cash and cash equivalents, beginning of period	323.4			245.2			230.9					—				799.5
Cash and cash equivalents, end of period	$	424.7		$	233.6		$	233.2				$	—			$	891.5
CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS
For the Three Months Ended September 28, 2013
(in millions)
	Unconsolidated
	Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminating Entries				Consolidated
Net cash from (for) operating activities	$	52.9		$	45.8		$	—			$	98.7
Cash Flows From (For) Investing Activities
Additions to property and equipment	(31.2		)	(9.2		)	—				(40.4		)
Proceeds from sale of land	—			4.6			—				4.6
Net cash from (for) investing activities	(31.2		)	(4.6		)	—				(35.8		)
Cash Flows From (For) Financing Activities											—
Cash dividends	(8.5		)	—			—				(8.5		)
Repurchase of common stock	(7.3		)	—			—				(7.3		)
Borrowings (repayments) of short-term debt, net	—			1.1			—				1.1
Issuance of common stock	3.5			—			—				3.5
Excess tax benefit of stock transactions	7.2			—			—				7.2
Deferred financing fees	(24.8		)	—			—				(24.8		)
Net cash from (for) financing activities	(29.9		)	1.1			—				(28.8		)
Effect of exchange rate changes on cash	—			2.6			—				2.6
Net increase (decrease) in cash and cash equivalents	(8.2		)	44.9			—				36.7
Cash and cash equivalents, beginning of period	519.6			260.3			—				779.9
Cash and cash equivalents, end of period	$	511.4		$	305.2		$	—			$	816.6

Subsequent_events

Subsequent events	3 Months Ended
	Sep. 27, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	– SUBSEQUENT EVENTS
	Perrigo Finance plc - On November 4, 2014, Perrigo Finance plc, a public limited company incorporated under the laws of Ireland, became a direct subsidiary of the Company.  Perrigo Finance plc is a 100% owned finance subsidiary of the Company, as defined in Rule 3-10(b) of Regulation S-X. Perrigo Finance plc expects to issue debt securities that will be fully and unconditionally guaranteed by the Company.  No other subsidiary of the Company will guarantee such indebtedness.
	Omega Pharma Invest NV - On November 6, 2014, the Company entered into an Agreement for the Sale and Purchase of 685,348,257 Shares of Omega Pharma Invest NV (“Omega”) (the “Share Purchase Agreement”) with Alychlo NV (“Alychlo”) and Holdco I BE NV (“Holdco” and, together with Alychlo, the “Sellers”), limited liability companies incorporated under the laws of Belgium, pursuant to which the Company will purchase (the “Acquisition”) from the Sellers 685,348,257 shares (the “Shares”) of Omega Pharma Invest NV (“Omega”), a limited liability company incorporated under the laws of Belgium, representing 95.77% of the issued and outstanding share capital of Omega. The remaining shares of Omega (30,243,983 shares) will be held by Omega as treasury shares.
	The Company agreed to acquire Omega for a total value of EUR 3.6 billion in equity and cash, which includes the assumption of EUR 1.1 billion in debt. The consideration will consist of cash of EUR 1.8 billion (the “Cash Consideration”) and 5,397,711 shares of the Company issued to Alychlo (the “Non-Cash Consideration” and, together with the Cash Consideration, the “Acquisition Consideration”). The Acquisition Consideration will be increased by interest from September 30, 2014 until the completion date on an amount of EUR 2.48 billion starting at a rate of 5% subject to monthly increases as set forth in the Share Purchase Agreement.
	The Cash Consideration will be financed by borrowings under credit facilities of the Company and/or issuances of debt and/or equity of the Company and/or its subsidiaries.
	The Sellers have agreed to indemnify the Company for certain losses. The Sellers’ indemnification and other obligations to the Company under the Share Purchase Agreement will be secured up to EUR 248.0 million.
	In connection with the Acquisition, the Company will assume or repay/redeem all outstanding indebtedness of Omega and its subsidiaries, which includes (i) EUR 135.0 million of 5.1045% senior notes due 2023 and USD 20.0 million (after hedging arrangements, EUR 16.2 million) of 6.19% senior notes due 2016, (ii) EUR 300.0 million of 5.125% retail bonds due 2017, EUR 180.0 million of 4.500% retail bonds due 2017, and EUR 120.0 million of 5.000% retail bonds due 2019, (iii) approximately EUR 390.0 million outstanding (with additional amounts available to be drawn) under certain credit and overdraft facilities, and (iv) amounts incurred under various cash pooling and overdraft arrangements.
	The Acquisition is conditioned upon customary closing conditions, including antitrust approval, accuracy of representations and warranties, compliance with covenants and no material adverse effect. The Company is obligated to use its best efforts to satisfy the antitrust approval condition, including making any required divestitures. Subject to the closing conditions, the Acquisition is expected to be completed during the third quarter of fiscal 2015.
	Under the terms of the Share Purchase Agreement, Alychlo and its affiliates will be subject to a three-year non-compete in Europe and Belgium, and the Sellers will be subject to a two-year non-solicit, in each case subject to certain exceptions.
	The Share Purchase Agreement contains other customary representations, warranties, and covenants of the parties thereto.
	Also on November 6, 2014, the Company entered into a Senior Unsecured 364-Day Bridge Facility Commitment Letter (the “Bridge Commitment Letter”) and a Senior Unsecured Credit Facilities Commitment Letter (the “Senior Commitment Letter” and, together with the Bridge Commitment Letter, the “Commitment Letters” and, the commitments thereunder, the “Commitments”) pursuant to which JPMorgan Chase Bank, N.A. and Barclays Bank PLC have committed to: (i) provide up to EUR 1.75 billion under a 364-day senior unsecured bridge loan facility (the “Bridge Loan Facility”); (ii) (x) solicit consents to amend the terms of the Company’s existing term loan credit agreement (the “Existing Term Loan Credit Agreement”) to permit the Acquisition, (y) replace the Existing Term Loan Credit Agreement with a backstop term loan facility permitting the Acquisition and otherwise containing the same terms and commitments as the Existing Term Loan Agreement, or (z) replace the Existing Term Loan Credit Agreement by entering into a new term loan credit agreement providing for increased commitments up to an aggregate principal amount of USD 300.0 million and EUR 800.0 million (any such amended, backstop, or new agreement, the “New Term Loan Facility”); and (iii) (x) solicit consents to amend the terms of the Company’s existing revolving credit agreement (the “Existing Revolving Credit Agreement”) to permit the Acquisition, (y) replace the Existing Revolving Credit Agreement with a backstop revolving facility permitting the Acquisition and otherwise containing the same terms and commitments as the Existing Revolving Credit Agreement, or (z) replace the Existing Revolving Credit Agreement by entering into a new revolving credit agreement providing for increased commitments up to an aggregate principal amount of USD 1.0 billion (any such amended, backstop, or new agreement, the “New Revolving Facility” and, together with the Bridge Facility and the New Term Loan Facility, the “New Facilities”). The Commitments are subject to various conditions, including the absence of any Material Adverse Effect (as defined in the Commitment Letters) on Omega and its subsidiaries, the negotiation of definitive documentation with respect to the New Facilities, and the other closing conditions set forth in the Commitment Letters.
	Concurrent with the announcement of the Acquisition, the Company entered into foreign currency option contracts to partly mitigate the currency exchange risk associated with the payment of the Euro-denominated purchase price.  These foreign currency option contracts will not be designated as hedging instruments and therefore changes in the derivatives fair value will be recorded in Other expense/income (net) on the Condensed Consolidated Statement of Operations.
	Lumara Health, Inc. - On September 29, 2014, the Company announced a definitive agreement to acquire a portfolio of women's healthcare products from Lumara Health, Inc., a privately-held, Chesterfield, Missouri-based specialty pharmaceutical company, for $83.0 million in cash. The acquisition was completed on October 31, 2014.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)	3 Months Ended
	Sep. 27, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes included in Perrigo Company plc's Annual Report on Form 10-K for the year ended June 28, 2014. In the opinion of management, all adjustments (consisting of normal recurring accruals and other adjustments) considered necessary for a fair presentation have been included.
	The Company’s sales of OTC pharmaceutical products are subject to the seasonal demands for cough/cold/flu and allergy products and consumer dynamics in the retail environments in which our customers operate. In addition, the Company's animal health products are subject to the seasonal demand for flea and tick products, which typically peaks during the warmer weather months. Accordingly, operating results for the three months ended September 27, 2014 are not necessarily indicative of the results that may be expected for a full fiscal year.
Consolidation, Policy [Policy Text Block]	'
	Principles of consolidation
	The condensed consolidated financial statements include the accounts of the Company, all majority-owned subsidiaries, and for the three months ended September 28, 2013, a variable-interest entity ("VIE"). Activities related to the VIE were immaterial. All intercompany transactions and balances have been eliminated in consolidation.
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	'
	Recently adopted accounting standards
	In July 2013, the Financial Accounting Standards Board issued Accounting Standards Update 2013-11, "Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists" ("ASU 2013-11"). The amendments in ASU 2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The Company prospectively adopted this guidance in fiscal 2015, and has presented $90.2 million as a reclassification from Non-current deferred income taxes to Other non-current liabilities on the Condensed Consolidated Balance Sheets.

Business_Acquisitions_Tables

Business Acquisitions (Tables)	3 Months Ended
	Sep. 27, 2014
Business Acquisition [Line Items]	'
Business Combination, Separately Recognized Transactions [Table Text Block]	'
	The below table indicates the purchase price allocation for fiscal 2014 acquisitions (in millions):
		Aspen			Fera		Elan
	Purchase price paid	$	53.7		$	17.3	$	9,451.90
	Contingent consideration	—			0.8		—
	Total purchase consideration	$	53.7		$	18.1	$	9,451.90
	Assets acquired:
	Cash and cash equivalents	$	—		$	—	$	1,807.30
	Investment securities	—			—		100
	Accounts receivable	—			—		44.2
	Inventories	2.7			0.3		—
	Prepaid expenses and other current assets	—			—		27.1
	Property and equipment	—			—		9.2
	Goodwill	4.6			—		2,333.10
	Intangible assets:
	Trade names and trademarks	34.8			—		—
	Customer relationships	9.8			—		—
	Non-competition agreements	1.8			—		—
	Distribution and license agreements	—			17.8		5,811.00
	Intangible assets	46.4			17.8		5,811.00
	Other non-current assets	—			—		93.4
	Total assets	53.7			18.1		10,225.30
	Liabilities assumed:
	Accounts payable	—			—		2
	Accrued liabilities	—			—		120.8
	Deferred tax liabilities	—			—		631.8
	Other non-current liabilities	—			—		18.8
	Total liabilities	—			—		773.4
	Net assets acquired	$	53.7		$	18.1	$	9,451.90
Elan Corporation [Member]	'
Business Acquisition [Line Items]	'
Fair value of consideration transferred in business acquisition [Table Text Block]	'
	Elan Corporation, plc – On December 18, 2013, the Company acquired Elan in a cash and stock transaction as follows (in millions, except per share data):
	Elan shares outstanding as of December 18, 2013		515.7
	Exchange ratio per share		0.07636
	Total Perrigo shares issued to Elan shareholders		39.4
	Perrigo per share value at transaction close on December 18, 2013		$	155.34
	Total value of Perrigo shares issued to Elan shareholders		6,117.20
	Cash consideration paid at $6.25 per Elan share		3,223.20
	Cash consideration paid for vested Elan stock options and share awards		111.5
	Total consideration		$	9,451.90
Schedule of acquisition-related costs [Table Text Block]	'
	The table below details these transaction costs and where they were recorded in the Consolidated Statement of Income for fiscal 2014 (in millions).
	Line item		Fiscal 2014
	Administration		$	108.9
	Interest expense, net		10
	Other expense (income), net		0.2
	Loss on extinguishment of debt		165.8
	Total acquisition-related costs		$	284.9
Business Combination, Segment Allocation [Table Text Block]	'
	The following table reflects the allocation by reportable segment (in millions):
	Segment		Goodwill
	Consumer Healthcare		$	1,110.00
	Rx Pharmaceuticals		845.1
	Nutritionals		177.4
	Specialty Sciences		200.6
	Total		$	2,333.10

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Sep. 27, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill [Table Text Block]	'
	Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
	Reporting Segments:		Balance at June 28, 2014			Business acquisitions			Purchase accounting adjustments				Currency translation adjustment			Balance at September 27, 2014
	Consumer Healthcare		$	1,406.30		$	—		$	(6.2	)		$	(4.6	)	$	1,395.50
	Nutritionals		510.1			—			(1.0		)		—			509.1
	Rx Pharmaceuticals		1,258.30			—			(4.7		)		(12.9		)	1,240.70
	API		97.6			—			—				(6.7		)	90.9
	Specialty Sciences		201.8			—			(1.1		)		—			200.7
	Total goodwill		$	3,474.10		$	—		$	(13.0	)		$	(24.2	)	$	3,436.90
Schedule of Finite and Indefinite-Lived Intangible Assets [Table Text Block]	'
	Other intangible assets and related accumulated amortization consisted of the following (in millions):
		September 27, 2014						June 28, 2014
		Gross			Accumulated Amortization			Gross				Accumulated Amortization
	Amortizable intangibles:
	Distribution and license agreements	$	6,026.50		$	269.4		$	6,027.30			$	192.1
	Developed product technology/formulation and product rights	916.9			316.5			931.7				302.5
	Customer relationships	369.2			101.8			372				97.5
	Trade names and trademarks	47.5			5.8			47.8				5.6
	Non-compete agreements	15.1			9.9			15.3				9.4
	Total	$	7,375.20		$	703.4		$	7,394.10			$	607.1
	Non-amortizable intangibles:
	Trade names and trademarks	$	58.4		$	—		$	59.5			$	—
	In-process research and development	7.7			—			10.2				—
	Total	66.1			—			69.7				—
	Total other intangible assets	$	7,441.30		$	703.4		$	7,463.80			$	607.1

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Sep. 27, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Major components of inventory at September 27, 2014 and June 28, 2014, were as follows (in millions):
		September 27,		June 28,
		2014		2014
	Finished goods	$	322.9	$	307
	Work in process	154.3		146.7
	Raw materials	179.6		177.9
	Total inventories	$	656.8	$	631.6

Fair_value_measurements_Tables

Fair value measurements (Tables)	3 Months Ended
	Sep. 27, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The following tables summarize the valuation of the Company’s financial instruments carried at fair value by the above pricing categories at September 27, 2014 and June 28, 2014 (in millions):
		27-Sep-14
		Level 1			Level 2				Level 3			Total
	Assets:
	Investment securities	$	21.6		$	—			$	—		$	21.6
	Foreign currency forward contracts	—			1.1				—			1.1
	Funds associated with Israeli post employment benefits	—			18.1				—			18.1
	Total assets	$	21.6		$	19.2			$	—		$	40.8
	Liabilities:
	Contingent consideration	$	—		$	—			$	12.4		$	12.4
	Interest rate swap agreements	—			6.9				—			6.9
	Foreign currency forward contracts	—			6.5				—			6.5
	Total liabilities	$	—		$	13.4			$	12.4		$	25.8
		28-Jun-14
		Level 1			Level 2				Level 3			Total
	Assets:
	Investment securities	$	20.7		$	—			$	—		$	20.7
	Foreign currency forward contracts	—			3.1				—			3.1
	Funds associated with Israeli post-employment benefits	—			19.3				—			19.3
	Total assets	$	20.7		$	22.4			$	—		$	43.1
	Liabilities:
	Contingent consideration	$	—		$	—			$	17.4		$	17.4
	Interest rate swap agreements	—			8.3				—			8.3
	Foreign currency forward contracts	—			0.8				—			0.8
	Total liabilities	$	—		$	9.1			$	17.4		$	26.5
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The tables below present a reconciliation for assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended September 27, 2014 and September 28, 2013 (in millions):
		Balance at June 28, 2014		Net realized investment gains (losses) and net change in unrealized appreciation (depreciation) included in net income (loss)			Net change in unrealized appreciation (depreciation) included in other comprehensive income (loss)			Purchases or Additions		Sales		Settlements			Balance at September 27, 2014
	Liabilities:
	Contingent consideration	$	17.4	$	—		$	—		$	—	$	—	$	(5.0	)	$	12.4
		Balance at June 29, 2013		Net realized investment gains (losses) and net change in unrealized appreciation (depreciation) included in net income (loss)			Net change in unrealized appreciation (depreciation) included in other comprehensive income (loss)			Purchases or Additions		Sales		Settlements			Balance at September 28, 2013
	Liabilities:
	Contingent Consideration	$	22.2	$	—		$	—		$	—	$	—	$	—		$	22.2

Investments_Tables

Investments (Tables)	3 Months Ended
	Sep. 27, 2014
Investments [Abstract]	'
Unrealized Gain (Loss) on Investments [Table Text Block]	'
	Net unrealized investment gains (losses) on available for sale securities were as follows (in millions):
		September 27, 2014			June 28,
					2014
	Net unrealized investment gains (losses):
	Equity securities, at cost less impairments	$	17.1		$	17.1
	Gross unrealized gains	4.9			3.8
	Gross unrealized losses	(0.4		)	(0.2		)
	Estimated fair value of equity securities	$	21.6		$	20.7

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Activities (Tables)	3 Months Ended
	Sep. 27, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	'
	The balance sheet location and gross fair value of the Company's derivative instruments at September 27, 2014 and June 28, 2014 were as follows (in millions):
		Asset Derivatives
		Balance Sheet Location		Fair Value
				September 27, 2014				June 28, 2014
	Hedging derivatives:
	Foreign currency forward contracts	Other current assets		$	0.4			$	2.8
	Total hedging derivatives			$	0.4			$	2.8
	Non-hedging derivatives:
	Foreign currency forward contracts	Other current assets		$	0.7			$	0.3
	Total non-hedging derivatives			$	0.7			$	0.3
		Liability Derivatives
		Balance Sheet Location		Fair Value
				September 27, 2014				June 28, 2014
	Hedging derivatives:
	Foreign currency forward contracts	Accrued liabilities		$	4.1			$	0.7
	Interest rate swap agreements	Other non-current liabilities		6.9				8.3
	Total hedging derivatives			$	11			$	9
	Non-hedging derivatives:
	Foreign currency forward contracts	Accrued liabilities		$	2.4			$	0.1
	Total non-hedging derivatives			$	2.4			$	0.1
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	'
	The effects (gross of tax) of the Company's cash flow hedges on the Condensed Consolidated Statements of Operations and Condensed Consolidated Statements of Other Comprehensive Income at September 27, 2014 and September 28, 2013 were as follows (in millions):
	Derivatives Qualifying for Cash		Amount of Gain/								Location and Amount of Gain/(Loss)								Location and Amount of Gain/(Loss)
	Flow Hedging		(Loss) Recognized in OCI on Derivative (Effective Portion)								Reclassified from Accumulated OCI into Income								Recognized in Income on Derivative
											(Effective Portion)								(Ineffective Portion and Amount Excluded from Effectiveness Testing)
			September 27, 2014				September 28, 2013						September 27, 2014			September 28, 2013				September 27, 2014		September 28, 2013
	T-Locks		$	—			$	—			Interest expense, net		$	—		$	0.1		Interest expense, net	$	—	$	—
	Interest rate swap agreements		2.7				(15.7		)		Interest expense, net		(0.9		)	(1.3		)	Interest expense, net	—		—
	Foreign currency forward contracts		(5.2		)		2.7				Net sales		0.6			0.7			Net sales	—		—
											Cost of sales		0.4			(1.0		)	Cost of sales	—		(0.4		)
											Interest expense, net		—			0.1
											Other expense (income), net		(0.8		)	1
	Total		$	(2.5	)		$	(13.0	)				$	(0.7	)	$	(0.4	)		$	—	$	(0.4	)
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	'
	The effects (gross of tax) of the Company's fair value hedges on the Condensed Consolidated Statements of Operations for three months ended September 28, 2013 were as follows (in millions):
	Fair Value Hedges		Location and Amount of (Gain)/Loss Recognized into Income					Related Hedged Item		Location and Amount of (Gain)/Loss Recognized in Income on Related Hedged Item
				September 28, 2013							September 28, 2013
	Interest rate swap agreements		Other expense (income), net	$	(6.7	)		Fixed-rate debt		Other expense (income), net	$	8.4

Indebtedness_Tables

Indebtedness (Tables)	3 Months Ended
	Sep. 27, 2014
Aggregate Indebtedness [Abstract]	'
Schedule of Debt [Table Text Block]	'
	Total borrowings outstanding are summarized as follows (in millions):
		September 27,			June 28,
		2014			2014
	Short term debt	$	—		$	2.1
	Term loans
	2013 Term Loan due December 15, 2015	300			300
	2013 Term Loan due December 15, 2018	595			630
		895			930
	Senior notes
	1.30% Unsecured Senior Notes due November 8, 2016, including unamortized discount of $0.4 million(1)	499.6			499.6
	2.30% Unsecured Senior Notes due November 8, 2018, including unamortized discount of $0.7 million(1)	599.3			599.3
	4.00% Unsecured Senior Notes due November 15, 2023, including unamortized discount of $3.1 million(1)	796.8			796.8
	5.30% Unsecured Senior Notes due November 15, 2043, including unamortized discount of $1.7 million(1)	398.3			398.3
		2,294.00			2,294.00
	Other financing	3.3			8.1
	Total borrowings outstanding	3,192.30			3,234.20
	Less short-term debt and current portion of long-term debt	(141.5		)	(143.7		)
	Total long-term debt, less current portion	$	3,050.80		$	3,090.50
	(1) Private placement unsecured senior notes with registration rights discussed below collectively as the "Bonds."
Schedule of Extinguishment of Debt [Table Text Block]	'
	As a result of the debt retirements, the Company recorded a loss of $165.8 million during the second quarter of fiscal 2014 as follows (in millions):
	Make-whole payments		$	133.5
	Write-off of financing fees on Bridge Credit Agreements		19
	Write-off of deferred financing fees		10.5
	Write-off of unamortized discount		2.8
	Total loss on extinguishment of debt		$	165.8

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Sep. 27, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):
		Three Months Ended
		September 27,		September 28,
		2014		2013
	Numerator:
	Net income	$	96.3	$	111.4
	Denominator:
	Weighted average shares outstanding for basic EPS	133.9		94.2
	Dilutive effect of share-based awards	0.5		0.5
	Weighted average shares outstanding for diluted EPS	134.4		94.7
	Anti-dilutive share-based awards excluded from computation of diluted EPS	0.1		0.1

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Sep. 27, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
	Changes in the Company's AOCI balances, net of tax, for the three months ended September 27, 2014 were as follows (in millions):
		Foreign			Fair value			Fair value of		Post-			Total AOCI
		currency			of derivative			investment		retirement and pension
		translation			financial			securities,		liability
		adjustments			instruments,			net of tax		adjustments,
					net of tax					net of tax
	Balance at June 28, 2014	$	164.4		$	(16.1	)	$	2.4	$	(11.1	)	$	139.6
	OCI before reclassifications	(63.8		)	(1.7		)	0.6		—			(64.9		)
	Amounts reclassified from AOCI	—			(0.4		)	—		—			(0.4		)
	Other comprehensive income	(63.8		)	(2.1		)	0.6		—			(65.3		)
	Balance at September 27, 2014	$	100.6		$	(18.2	)	$	3	$	(11.1	)	$	74.3

Restructuring_Tables

Restructuring (Tables)	3 Months Ended
	Sep. 27, 2014
Restructuring Charges [Abstract]	'
Restructuring and Related Costs [Table Text Block]	'
	The following summarizes the Company's restructuring activity for the three months ended September 27, 2014 and September 28, 2013 (in millions):
		Three Months Ended
		27-Sep-14			28-Sep-13
	Beginning balance	$	16.4		$	2.9
	Additional charges	1.7			2.1
	Payments	(13.5		)	(1.4		)
	Non-cash adjustments	(0.7		)	—
	Ending balance	$	3.9		$	3.6

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Sep. 27, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
		Three Months Ended
		27-Sep-14
		Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
	Consumer Healthcare	$	493.3	$	65.3		$	8.6	$	3,828.00
	Nutritionals	125.3		8.6			7.2		1,072.60
	Rx Pharmaceuticals	194.5		64.7			17		2,509.10
	API	24.8		7.1			0.5		251.2
	Specialty Sciences	91.9		14.9			72.8		6,023.00
	Other	21.7		0.9			0.4		97.1
	Unallocated expenses	—		(24.3		)	—		—
	Total	$	951.5	$	137.2		$	106.5	$	13,781.00
		Three Months Ended
		28-Sep-13
		Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
	Consumer Healthcare	$	538.5	$	89.9		$	5.3	$	2,508.60
	Nutritionals	129		7.7			7.4		930.7
	Rx Pharmaceuticals	203.6		83.1			16.2		1,669.00
	API	43.2		22.4			0.5		295.2
	Specialty Sciences	—		—			—		—
	Other	19.1		1.2			0.4		105.3
	Unallocated expenses	—		(24.6		)	—		—
	Total	$	933.4	$	179.7		$	29.8	$	5,508.80

Guarantor_Financials_Tables

Guarantor Financials (Tables)	3 Months Ended
	Sep. 27, 2014																			Sep. 28, 2013
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'																			'
Condensed Income Statement [Table Text Block]	'																			'
		Unconsolidated																			Unconsolidated
		Perrigo Company plc			Guarantor Subsidiaries			Non-Guarantor Subsidiaries				Eliminating Entries				Consolidated					Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminating Entries			Consolidated
	Net sales	$	—		$	829.7		$	263.7			$	(141.9	)		$	951.5			Net sales	$	802.1		$	276.4		$	(145.1	)	$	933.4
	Cost of sales	—			582.1			169.2				(121.6		)		629.7				Cost of sales	537			168.2			(128.1		)	577.1
	Gross profit	—			247.6			94.5				(20.3		)		321.8				Gross profit	265.1			108.2			(17.0		)	356.3
	Operating expenses																			Operating expenses
	Distribution	—			11			3.4				—				14.4				Distribution	10.6			2.6			—			13.2
	Research and development	—			21.7			14.9				—				36.6				Research and development	21.8			10.5			—			32.3
	Selling	—			39.8			10.6				—				50.4				Selling	39.8			10.4			—			50.2
	Administration	13.7			51.1			17.2				(0.5		)		81.5				Administration	71			7.8			—			78.8
	Restructuring	—			1.7			—				—				1.7				Restructuring	2.1			—			—			2.1
	Total operating expenses	13.7			125.3			46.1				(0.5		)		184.6				Total operating expenses	145.3			31.3			—			176.6
	Operating income (loss)	(13.7		)	122.3			48.4				(19.8		)		137.2				Operating income (loss)	119.8			76.9			(17.0		)	179.7
	Interest expense, net	23.9			192.6			(190.5		)		(0.1		)		25.9				Interest expense, net	20.1			1.3			—			21.4
	Other expense (income), net	—			(1.8		)	3.8				0.7				2.7				Other expense (income), net	0.9			0.1			—			1
	Income (loss) before income taxes and equity in net income (loss) of subsidiaries	(37.6		)	(68.5		)	235.1				(20.4		)		108.6				Income (loss) before income taxes and equity in net income (loss) of subsidiaries	98.8			75.5			(17.0		)	157.3
	Income tax expense	(1.6		)	3.6			10.3				—				12.3				Income tax expense	42.2			3.7			—			45.9
	Income (loss) before equity in net income (loss) of subsidiaries	(36.0		)	(72.1		)	224.8				(20.4		)		96.3				Income (loss) before equity in net income (loss) of subsidiaries	56.6			71.8			(17.0		)	111.4
	Equity in net income (loss) of subsidiaries	132.3			54.6			35.8				(222.7		)		—				Equity in net income (loss) of subsidiaries	54.8			30.8			(85.6		)	—
	Net income (loss)	$	96.3		$	(17.5	)	$	260.6			$	(243.1	)		$	96.3			Net income (loss)	$	111.4		$	102.6		$	(102.6	)	$	111.4
Condensed Statement of Comprehensive Income [Table Text Block]	'																			'
		Unconsolidated																			Unconsolidated
		Perrigo Company plc			Guarantor Subsidiaries			Non-Guarantor Subsidiaries				Eliminating Entries				Consolidated					Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminating Entries			Consolidated
	Net income (loss)	$	96.3		$	(17.5	)	$	260.6			$	(243.1	)		$	96.3			Net income	$	111.4		$	102.6		$	(102.6	)	$	111.4
	Other comprehensive income (loss):																			Other comprehensive income (loss):
	Foreign currency translation adjustments	(63.8		)	(0.2		)	(63.6		)		63.8				(63.8		)		Foreign currency translation adjustments	36.6			37.2			(37.2		)	36.6
	Change in fair value of derivative financial instruments, net of tax	(2.1		)	0.9			(0.5		)		(0.4		)		(2.1		)		Change in fair value of derivative financial instruments, net of tax	(9.2		)	0.3			(0.3		)	(9.2		)
	Change in fair value of investment securities, net of tax	0.6			(1.3		)	3				(1.7		)		0.6				Change in fair value of investment securities, net of tax	—			—			—			—
	Change in post-retirement and pension liability adjustments, net of tax	—			—			—				—				—				Change in post-retirement and pension liability adjustments, net of tax	(0.1		)	—			—			(0.1		)
	Other comprehensive income (loss), net of tax	(65.3		)	(0.6		)	(61.1		)		61.7				(65.3		)		Other comprehensive income (loss), net of tax	27.3			37.5			(37.5		)	27.3
	Comprehensive income (loss)	$	31		$	(18.1	)	$	199.5			$	(181.4	)		$	31			Comprehensive income	$	138.7		$	140.1		$	(140.1	)	$	138.7
Condensed Balance Sheet [Table Text Block]	'																			'
		Unconsolidated																			Unconsolidated
		Perrigo Company plc			Guarantor Subsidiaries			Non-Guarantor Subsidiaries				Eliminating Entries				Consolidated					Perrigo Company plc			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminating Entries			Consolidated
	Assets																			Assets
	Cash and cash equivalents	$	424.7		$	233.6		$	233.2			$	—			$	891.5			Cash and cash equivalents	$	323.4		$	245.2		$	230.9		$	—		$	799.5
	Investment securities	—			16.5			5.1				—				21.6				Investment securities	—			—			5.9			—			5.9
	Accounts receivable, net	2			283			1,822.60				(1,238.2		)		869.4				Accounts receivable, net	1.4			463.9			4,495.70			(4,025.9		)	935.1
	Inventories	—			658.4			148.1				(149.7		)		656.8				Inventories	—			613.9			148.1			(130.4		)	631.6
	Current deferred income taxes	—			61.3			3.3				—				64.6				Current deferred income taxes	—			59.8			3			—			62.8
	Prepaid expenses and other current assets	20.6			60.1			49.4				—				130.1				Prepaid expenses and other current assets	9.9			62.7			43.4			—			116
	Total current assets	447.3			1,312.90			2,261.70				(1,387.9		)		2,634.00				Total current assets	334.7			1,445.50			4,927.00			(4,156.3		)	2,550.90
	Property and equipment, net	—			526.4			235.3				—				761.7				Property and equipment, net	—			532.4			247.5			—			779.9
	Goodwill and other indefinite-lived intangible assets	—			3,065.30			437.7				—				3,503.00				Goodwill and other indefinite-lived intangible assets	—			3,078.30			465.5			—			3,543.80
	Other intangible assets, net	—			6,475.40			196.4				—				6,671.80				Other intangible assets, net	—			6,583.80			203.2			—			6,787.00
	Non-current deferred income taxes	14.4			10.9			3.2				—				28.5				Non-current deferred income taxes	16			—			23.6			(16.0		)	23.6
	Other non-current assets	23			74.5			84.5				—				182				Other non-current assets	23.8			84.5			86.7			—			195
	Intercompany loans receivable	7,300.00			2,065.70			14,242.30				(23,608.0		)		—				Intercompany loans receivable	7,300.00			2,145.70			11,444.10			(20,889.8		)	—
	Investments in subsidiaries	6,284.90			8,538.30			367.5				(15,190.7		)		—				Investments in subsidiaries	6,218.90			7,826.90			325.2			(14,371.0		)	—
	Total non-current assets	13,622.30			20,756.50			15,566.90				(38,798.7		)		11,147.00				Total non-current assets	13,558.70			20,251.60			12,795.80			(35,276.8		)	11,329.30
	Total assets	$	14,069.60		$	22,069.40		$	17,828.60			$	(40,186.6	)		$	13,781.00			Total assets	$	13,893.40		$	21,697.10		$	17,722.80		$	(39,433.1	)	$	13,880.20
	Liabilities and Shareholders’ Equity																			Liabilities and Shareholders’ Equity
	Accounts payable	$	40.4		$	1,254.00		$	252.2			$	(1,237.6	)		$	309			Accounts payable	$	35.2		$	3,998.00		$	487.3		$	(4,156.2	)	$	364.3
	Payroll and related taxes	0.1			56.2			20.7				—				77				Short-term debt	—			—			2.1			—			2.1
	Accrued customer programs	—			35			239.5				—				274.5				Payroll and related taxes	0.1			79.9			32.3			—			112.3
	Accrued liabilities	32.5			102.2			45.6				(0.4		)		179.9				Accrued customer programs	—			65.6			190.9			—			256.5
	Accrued income taxes	(0.6		)	12.7			19.6				—				31.7				Accrued liabilities	11.4			121.8			46.7			(0.5		)	179.4
	Current deferred income taxes	—			4.3			—				—				4.3				Accrued income taxes	—			3.4			14			—			17.4
	Current portion of long-term debt	140			1.5			—				—				141.5				Current deferred income taxes	—			1.1			—			—			1.1
	Total current liabilities	212.4			1,465.90			577.6				(1,238.0		)		1,017.90				Current portion of long-term debt	140			1.6			—			—			141.6
	Long-term debt, less current portion	3,049.20			1.6			—				—				3,050.80				Total current liabilities	186.7			4,271.40			773.3			(4,156.7		)	1,074.70
	Non-current deferred income taxes	—			692.2			16.5				—				708.7				Long-term debt, less current portion	3,084.00			1.9			4.6			—			3,090.50
	Other non-current liabilities	—			192.4			94.5				—				286.9				Non-current deferred income taxes	—			709.6			34.3			(16.0		)	727.9
	Intercompany loans payable	2,091.30			13,849.00			7,667.70				(23,608.0		)		—				Other non-current liabilities	—			182.6			110.8			—			293.4
	Total non-current liabilities	5,140.50			14,735.20			7,778.70				(23,608.0		)		4,046.40				Intercompany loans payable	1,929.00			11,291.50			7,667.80			(20,888.3		)	—
	Total liabilities	5,352.90			16,201.10			8,356.30				(24,846.0		)		5,064.30				Total non-current liabilities	5,013.00			12,185.60			7,817.50			(20,904.3		)	4,111.80
	Shareholders’ equity	8,716.70			5,868.30			9,472.30				(15,340.6		)		8,716.70				Total liabilities	5,199.70			16,457.00			8,590.80			(25,061.0		)	5,186.50
	Total liabilities and shareholders' equity	$	14,069.60		$	22,069.40		$	17,828.60			$	(40,186.6	)		$	13,781.00			Controlling interest	8,693.70			5,240.10			9,131.20			(14,372.1		)	8,692.90
																				Non-controlling interest	—			—			0.8			—			0.8
																				Shareholders’ equity	8,693.70			5,240.10			9,132.00			(14,372.1		)	8,693.70
																				Total liabilities and shareholders' equity	$	13,893.40		$	21,697.10		$	17,722.80		$	(39,433.1	)	$	13,880.20
Condensed Cash Flow Statement [Table Text Block]	'																			'
		Unconsolidated																			Unconsolidated
		Perrigo Company plc			Guarantor Subsidiaries			Non-Guarantor Subsidiaries					Eliminating Entries				Consolidated				Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminating Entries			Consolidated
	Net cash from (for) operating activities	$	(91.2	)	$	211.3		$	75		—		$	—			$	195.1		Net cash from (for) operating activities	$	52.9		$	45.8		$	—		$	98.7
	Cash Flows From (For) Investing Activities																			Cash Flows From (For) Investing Activities
	Additions to property and equipment	—			(18.4		)	(13.3		)			—				(31.7		)	Additions to property and equipment	(31.2		)	(9.2		)	—			(40.4		)
	(Purchase) return of investment	—			1.2			(1.3		)			—				(0.1		)	Proceeds from sale of land	—			4.6			—			4.6
	Proceeds from sale of business	—			—			1.1					—				1.1			Net cash from (for) investing activities	(31.2		)	(4.6		)	—			(35.8		)
	Intercompany notes issued	—			(202.1		)	(243.6		)			445.7				—			Cash Flows From (For) Financing Activities										—
	Net cash from (for) investing activities	—			(219.3		)	(257.1		)			445.7				(30.7		)	Cash dividends	(8.5		)	—			—			(8.5		)
	Cash Flows From (For) Financing Activities																—			Repurchase of common stock	(7.3		)	—			—			(7.3		)
	Repayments of long-term debt	(35.0		)	—			(4.5		)			—				(39.5		)	Borrowings (repayments) of short-term debt, net	—			1.1			—			1.1
	Cash dividends	(14.1		)	—			—					—				(14.1		)	Issuance of common stock	3.5			—			—			3.5
	Repurchase of common stock	(7.5		)	—			—					—				(7.5		)	Excess tax benefit of stock transactions	7.2			—			—			7.2
	Settlements of contingent consideration	—			(5.0		)	—					—				(5.0		)	Deferred financing fees	(24.8		)	—			—			(24.8		)
	Borrowings (repayments) of short-term debt, net	—			—			(2.1		)			—				(2.1		)	Net cash from (for) financing activities	(29.9		)	1.1			—			(28.8		)
	Issuance of common stock	2.6			—			—					—				2.6			Effect of exchange rate changes on cash	—			2.6			—			2.6
	Excess tax benefit of stock transactions	4.3			—			—					—				4.3			Net increase (decrease) in cash and cash equivalents	(8.2		)	44.9			—			36.7
	Intercompany notes borrowed	242.2			1.4			202.1					(445.7		)		—			Cash and cash equivalents, beginning of period	519.6			260.3			—			779.9
	Net cash from (for) financing activities	192.5			(3.6		)	195.5					(445.7		)		(61.3		)	Cash and cash equivalents, end of period	$	511.4		$	305.2		$	—		$	816.6
	Effect of exchange rate changes on cash	—			—			(11.1		)			—				(11.1		)
	Net increase (decrease) in cash and cash equivalents	101.3			(11.6		)	2.3					—				92
	Cash and cash equivalents, beginning of period	323.4			245.2			230.9					—				799.5
	Cash and cash equivalents, end of period	$	424.7		$	233.6		$	233.2				$	—			$	891.5

Summary_of_Significant_Account2

Summary of Significant Accounting Policies and Basis of Presentation Summary of Significant Accounting Policies - Tax (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014
Income Tax Disclosure [Abstract]	'
Increase (Decrease) in Deferred Income Taxes	$90.20

Business_Acquisitions_Details

Business Acquisitions (Details) (USD $)

Sep. 27, 2014

Jun. 28, 2014

Dec. 18, 2013

Dec. 18, 2013

Feb. 28, 2014

Sep. 27, 2014

Mar. 29, 2014

Feb. 28, 2014

Feb. 18, 2014

Sep. 27, 2014

Mar. 29, 2014

Feb. 18, 2014

Dec. 18, 2013

Sep. 27, 2014

Mar. 29, 2014

Jun. 28, 2014

Dec. 18, 2013

Dec. 28, 2013

Jun. 27, 2009

Aug. 06, 2009

Feb. 28, 2014

Feb. 18, 2014

Dec. 18, 2013

Feb. 28, 2014

Feb. 18, 2014

Dec. 18, 2013

Feb. 28, 2014

Feb. 18, 2014

Dec. 18, 2013

Sep. 27, 2014

1-May-14

Sep. 27, 2014

Feb. 28, 2014

Feb. 18, 2014

Dec. 18, 2013

Sep. 27, 2014

Sep. 27, 2014

Sep. 27, 2014

Sep. 27, 2014

Sep. 27, 2014

Jun. 28, 2014

Sep. 27, 2014

Sep. 27, 2014

Jun. 28, 2014

Sep. 27, 2014

Sep. 27, 2014

Jun. 28, 2014

Sep. 27, 2014

Sep. 27, 2014

Jun. 28, 2014

Sep. 27, 2014

Jun. 28, 2014

Jun. 28, 2014

Jun. 28, 2014

Jun. 28, 2014

Sep. 27, 2014

Sep. 27, 2014

Sep. 27, 2014

Sep. 27, 2014

Sep. 27, 2014

Sep. 27, 2014

Perrigo Company [Member]

Aspen Global [Member]

Aspen Global [Member]

Aspen Global [Member]

Aspen Global [Member]

Fera (methazolomide) [Member]

Fera (methazolomide) [Member]

Fera (methazolomide) [Member]

Fera (methazolomide) [Member]

Elan Corporation [Member]

Elan Corporation [Member]

Elan Corporation [Member]

Elan Corporation [Member]

Elan Corporation [Member]

Vedants Drug and Fine Chemicals Private Ltd [Member]

Vedants Drug and Fine Chemicals Private Ltd [Member]

Vedants Drug and Fine Chemicals Private Ltd [Member]

Trademarks and Trade Names [Member]

Trademarks and Trade Names [Member]

Trademarks and Trade Names [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Noncompete Agreements [Member]

Noncompete Agreements [Member]

Noncompete Agreements [Member]

Tysabri [Member]

Tysabri [Member]

Prialt [Member]

Distribution And License Agreements [Member]

Distribution And License Agreements [Member]

Distribution And License Agreements [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Consumer Healthcare [Member]

Consumer Healthcare [Member]

Consumer Healthcare [Member]

Nutritionals [Member]

Nutritionals [Member]

Nutritionals [Member]

Rx Pharmaceuticals [Member]

Rx Pharmaceuticals [Member]

Rx Pharmaceuticals [Member]

Specialty Sciences [Member]

Specialty Sciences [Member]

Specialty Sciences [Member]

General and Administrative Expense [Member]

Interest expense, net [Member]

Other expense (income), net [member]

Loss on extinguishment of debt [Member]

Elan Corporation [Member]

Elan Corporation [Member]

Fera (methazolomide) [Member]

Aspen Global [Member]

Aspen Global [Member]

Aspen Global [Member]

Aspen Global [Member]

Fera (methazolomide) [Member]

Elan Corporation [Member]

Aspen Global [Member]

Fera (methazolomide) [Member]

Elan Corporation [Member]

Aspen Global [Member]

Fera (methazolomide) [Member]

Elan Corporation [Member]

Aspen Global [Member]

Fera (methazolomide) [Member]

Elan Corporation [Member]

Tysabri [Member]

Prialt [Member]

Tysabri [Member]

Prialt [Member]

Elan Corporation [Member]

Elan Corporation [Member]

Elan Corporation [Member]

Elan Corporation [Member]

Elan Corporation [Member]

Elan Corporation [Member]

Elan Corporation [Member]

Elan Corporation [Member]

Tysabri [Member]

Prialt [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Trademarks and Trade Names [Member]

Noncompete Agreements [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Effective Date of Acquisition

'

'

'

'

'

28-Feb-14

'

'

'

18-Feb-14

'

'

'

18-Dec-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'20 years

'10 years

'15 years

'15 years

'25 years

'5 years

Shares, Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

515,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Share Exchange Ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.07636

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Company shares issued to acquired company shareholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

39,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Share Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$155.34

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Equity Interest Issued or Issuable, Value Assigned

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6,117,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Cash Exchange

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,223,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition, cash consideration paid for vested stock options and awards

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

111,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to Acquire Businesses, Gross

'

'

'

'

53,700,000

'

'

'

17,300,000

'

'

'

9,451,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition, cash consideration paid on unvested stock options and awards

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Cash Exchange per share

'

'

$6.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Percentage of Voting Interests Acquired

'

'

'

71.00%

'

'

'

'

'

'

'

'

'

'

'

'

29.00%

15.00%

'

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Acquisition Related Costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

284,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

108,900,000

10,000,000

200,000

165,800,000

'

'

'

'

'

'

Percent of royalty revenues generated by specific agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

'

18.00%

7.00%

25.00%

17.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sales Revenue, Goods, Net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000,000

'

2,000,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-lived Intangible Assets Acquired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,800,000,000

'

11,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

3,436,900,000

3,474,100,000

'

'

'

'

'

4,600,000

'

'

'

0

'

2,333,100,000

'

'

2,333,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,395,500,000

1,406,300,000

1,110,000,000

509,100,000

510,100,000

177,400,000

1,240,700,000

1,258,300,000

845,100,000

200,700,000

201,800,000

200,600,000

'

'

'

'

'

'

'

'

'

'

Business combination provisional adjustment, initial valuation incomplete, non-current liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

13,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration

12,400,000

17,400,000

'

'

'

'

'

0

'

'

'

800,000

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Consideration Transferred

'

'

'

'

'

'

53,700,000

'

'

'

18,100,000

'

'

'

9,451,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

1,807,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

business combination, recognized identifiable assets acquired and liabilities assumed, investments

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

44,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

'

'

'

'

'

'

'

2,700,000

'

'

'

300,000

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

27,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

9,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

'

'

'

'

'

'

'

46,400,000

'

'

'

17,800,000

'

'

'

'

5,811,000,000

'

'

'

34,800,000

0

0

9,800,000

0

0

1,800,000

0

0

'

'

'

0

17,800,000

5,811,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

93,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

'

'

'

'

'

'

'

53,700,000

'

'

'

18,100,000

'

'

'

'

10,225,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

120,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

631,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

18,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

773,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

'

'

'

'

'

'

'

53,700,000

'

'

'

18,100,000

'

'

'

'

9,451,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7,200,000

$11,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets - Goodwill (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014
Goodwill [Roll Forward]	'
Beginning balance	$3,474.10
Business acquisitions	0
Purchase Accounting Adjustments	-13
Currency translation adjustment	-24.2
Ending balance	3,436.90
Consumer Healthcare [Member]	'
Goodwill [Roll Forward]	'
Beginning balance	1,406.30
Business acquisitions	0
Purchase Accounting Adjustments	-6.2
Currency translation adjustment	-4.6
Ending balance	1,395.50
Nutritionals [Member]	'
Goodwill [Roll Forward]	'
Beginning balance	510.1
Business acquisitions	0
Purchase Accounting Adjustments	-1
Currency translation adjustment	0
Ending balance	509.1
Rx Pharmaceuticals [Member]	'
Goodwill [Roll Forward]	'
Beginning balance	1,258.30
Business acquisitions	0
Purchase Accounting Adjustments	-4.7
Currency translation adjustment	-12.9
Ending balance	1,240.70
API [Member]	'
Goodwill [Roll Forward]	'
Beginning balance	97.6
Business acquisitions	0
Purchase Accounting Adjustments	0
Currency translation adjustment	-6.7
Ending balance	90.9
Specialty Sciences [Member]	'
Goodwill [Roll Forward]	'
Beginning balance	201.8
Business acquisitions	0
Purchase Accounting Adjustments	-1.1
Currency translation adjustment	0
Ending balance	$200.70

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets - Intangible categories (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013	Jun. 28, 2014
Finite And Indefinite Lived Assets By Major Class [Line Items]	'	'	'
Intangible assets subject to amortization, Gross	$7,375.20	'	$7,394.10
Intangible assets subject to amortization, Accumulated Amortization	703.4	'	607.1
Intangible assets not subject to amortization	66.1	'	69.7
Total other intangible assets	7,441.30	'	7,463.80
Intangible assets amortization expense	106.5	29.8	'
Trade names and trademarks [Member]	'	'	'
Finite And Indefinite Lived Assets By Major Class [Line Items]	'	'	'
Intangible assets not subject to amortization	58.4	'	59.5
In Process Research and Development [Member]	'	'	'
Finite And Indefinite Lived Assets By Major Class [Line Items]	'	'	'
Intangible assets not subject to amortization	7.7	'	10.2
Distribution And License Agreements [Member]	'	'	'
Finite And Indefinite Lived Assets By Major Class [Line Items]	'	'	'
Intangible assets subject to amortization, Gross	6,026.50	'	6,027.30
Intangible assets subject to amortization, Accumulated Amortization	269.4	'	192.1
Developed Product Technology/Formulation and Product Rights [Member]	'	'	'
Finite And Indefinite Lived Assets By Major Class [Line Items]	'	'	'
Intangible assets subject to amortization, Gross	916.9	'	931.7
Intangible assets subject to amortization, Accumulated Amortization	316.5	'	302.5
Customer Relationships [Member]	'	'	'
Finite And Indefinite Lived Assets By Major Class [Line Items]	'	'	'
Intangible assets subject to amortization, Gross	369.2	'	372
Intangible assets subject to amortization, Accumulated Amortization	101.8	'	97.5
Trade names and trademarks [Member]	'	'	'
Finite And Indefinite Lived Assets By Major Class [Line Items]	'	'	'
Intangible assets subject to amortization, Gross	47.5	'	47.8
Intangible assets subject to amortization, Accumulated Amortization	5.8	'	5.6
Noncompete Agreements [Member]	'	'	'
Finite And Indefinite Lived Assets By Major Class [Line Items]	'	'	'
Intangible assets subject to amortization, Gross	15.1	'	15.3
Intangible assets subject to amortization, Accumulated Amortization	$9.90	'	$9.40

Inventories_Details

Inventories (Details) (USD $)	Sep. 27, 2014	Jun. 28, 2014
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Finished Goods	$322.90	$307
Work in Process	154.3	146.7
Raw Materials	179.6	177.9
Total inventories	$656.80	$631.60

Fair_value_measurements_assets

Fair value measurements - assets and liabilities on a recurring basis (Details) (USD $)	Sep. 27, 2014	Jun. 28, 2014	Nov. 08, 2013
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'	'
Senior Notes	$2,294	$2,294	$2,300
Assets:	'	'	'
Investment securities	21.6	20.7	'
Foreign currency forward contracts	1.1	3.1	'
Funds associated with Israeli post employment benefits	18.1	19.3	'
Total assets	40.8	43.1	'
Liabilities:	'	'	'
Contingent consideration	12.4	17.4	'
Interest rate swap agreements	6.9	8.3	'
Foreign currency forward contracts	6.5	0.8	'
Total liabilities	25.8	26.5	'
Fair Value, Inputs, Level 1 [Member]	'	'	'
Assets:	'	'	'
Investment securities	21.6	20.7	'
Foreign currency forward contracts	0	0	'
Funds associated with Israeli post employment benefits	0	0	'
Total assets	21.6	20.7	'
Liabilities:	'	'	'
Contingent consideration	0	0	'
Interest rate swap agreements	0	0	'
Foreign currency forward contracts	0	0	'
Total liabilities	0	0	'
Fair Value, Inputs, Level 2 [Member]	'	'	'
Assets:	'	'	'
Investment securities	0	0	'
Foreign currency forward contracts	1.1	3.1	'
Funds associated with Israeli post employment benefits	18.1	19.3	'
Total assets	19.2	22.4	'
Liabilities:	'	'	'
Contingent consideration	0	0	'
Interest rate swap agreements	6.9	8.3	'
Foreign currency forward contracts	6.5	0.8	'
Total liabilities	13.4	9.1	'
Fair Value, Inputs, Level 3 [Member]	'	'	'
Assets:	'	'	'
Investment securities	0	0	'
Foreign currency forward contracts	0	0	'
Funds associated with Israeli post employment benefits	0	0	'
Total assets	0	0	'
Liabilities:	'	'	'
Contingent consideration	12.4	17.4	'
Interest rate swap agreements	0	0	'
Foreign currency forward contracts	0	0	'
Total liabilities	12.4	17.4	'
Senior Notes and Public Bond [Domain] | Fair Value, Inputs, Level 2 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'	'
Senior Notes	$2,300	$2,400	'

Fair_value_measurements_level_

Fair value measurements - level 3 roll (Details) (Contingent Consideration Classified as Equity [Member], Fair Value, Inputs, Level 3 [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Contingent Consideration Classified as Equity [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Level 3 rollforward beginning balance	$17.40	$22.20
Net unrealized investment gains (losses) and net change in unrealized appreciation (depreciation) included in net income (loss)	0	0
Net change in unrealized appreciation (depreciation) included in other comprehensive income (loss)	0	0
Purchases or additions	0	0
Sales	0	0
Settlements	-5	0
Level 3 rollforward ending balance	$12.40	$22.20

Fair_Value_Measurements_Fair_v

Fair Value Measurements Fair value measurements - items not carried at fair value (Details) (USD $)	Sep. 27, 2014	Jun. 28, 2014	Nov. 08, 2013
In Millions, unless otherwise specified
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'	'
Senior Notes	$2,294	$2,294	$2,300

Investments_Details

Investments (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013	Jun. 28, 2014
Schedule of Equity Method Investments [Line Items]	'	'	'
Available-for-sale Securities	'	'	$20.70
Equity Method Investments	0	'	0
Unrealized loss on equity method investments	-3.1	0	'
Unrealized Gain (Loss) on Investments [Abstract]	'	'	'
Equity securities, at cost less impairments	17.1	'	17.1
Gross unrealized gains	4.9	'	3.8
Gross unrealized losses	-0.4	'	-0.2
Estimated fair value of equity securities	21.6	'	20.7
Available-for-sale Securities [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Available-for-sale Securities	21.6	'	5.9
Other Noncurrent Assets [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Available-for-sale Securities	'	'	14.8
Cost Method Investments	8.7	'	9
Equity Method Investments	$55.60	'	$57.40

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities - text links (Details) (USD $)	3 Months Ended
	Sep. 27, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 28, 2014	Sep. 06, 2013
Derivative [Line Items]	'	'	'	'	'
Derivative, Notional Amount	$441,000,000	'	'	$468,500,000	'
Term loans	895,000,000	'	'	930,000,000	1,000,000,000
Proceeds from Issuance of Debt	'	2,300,000,000	'	'	'
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	-2,500,000	'	-13,000,000	'	'
Interest Rate Swap [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	2,700,000	'	-15,700,000	'	'
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Derivative, Notional Amount	240,000,000	'	'	725,000,000	'
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	'	12,800,000	'	'	'
Foreign Exchange Forward [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	-5,200,000	'	2,700,000	'	'
Maximum Remaining Maturity of Foreign Currency Derivatives	'15 months	'	'	'	'
Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Derivative, Gain (Loss) on Derivative, Net	-3,300,000	'	-1,500,000	'	'
Fair Value Hedging [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Derivative, Notional Amount	425,000,000	'	'	'	'
Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net	'	'	$1,700,000	'	'

Derivative_Instruments_and_Hed3

Derivative Instruments and Hedging Activities - balance sheet location (Details) (USD $)	Sep. 27, 2014	Jun. 28, 2014
In Millions, unless otherwise specified
Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Asset, Fair Value, Net	$0.40	$2.80
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	11	9
Designated as Hedging Instrument [Member] | Other Current Assets [Member] | Foreign Exchange Forward [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Asset, Fair Value, Net	0.4	2.8
Designated as Hedging Instrument [Member] | Accrued Liabilities [Member] | Foreign Exchange Forward [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	4.1	0.7
Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member] | Interest Rate Swap [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	6.9	8.3
Not Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	2.4	0.1
Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Asset, Fair Value, Net	0.7	0.3
Not Designated as Hedging Instrument [Member] | Other Current Assets [Member] | Foreign Exchange Forward [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Asset, Fair Value, Net	0.7	0.3
Not Designated as Hedging Instrument [Member] | Accrued Liabilities [Member] | Foreign Exchange Forward [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	$2.40	$0.10

Derivative_Instruments_and_Hed4

Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities - other comprehensive income movement (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	($2.50)	($13)
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	-0.7	-0.4
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	-0.4
Treasury Lock Agreement [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	0	0
Interest Rate Swap [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	2.7	-15.7
Foreign Exchange Forward [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	-5.2	2.7
Interest Expense, net [Member] | Treasury Lock Agreement [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0	0.1
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0
Interest Expense, net [Member] | Interest Rate Swap [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	-0.9	-1.3
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0
Interest Expense, net [Member] | Foreign Exchange Forward [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0	0.1
Other expense (income), net [member] | Foreign Exchange Forward [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	-0.8	1
Net sales [Member] | Foreign Exchange Forward [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0.6	0.7
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0
Cost of Sales [Member] | Foreign Exchange Forward [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0.4	-1
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	$0	($0.40)

Derivative_Instruments_and_Hed5

Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities -Fair value hedges (Details) (Fair Value Hedging [Member], Other expense (income), net [member], USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Jun. 28, 2014
	Interest Rate Swap [Member]	Fixed-rate Debt [Member]
Derivative [Line Items]	'	'
Derivative, Gain (Loss) on Derivative, Net	($6.70)	$8.40

Indebtedness_Debt_arrangements

Indebtedness (Debt arrangements) (details) (USD $)

Sep. 27, 2014

Jun. 28, 2014

Nov. 08, 2013

Sep. 06, 2013

Sep. 27, 2014

Jun. 28, 2014

Sep. 06, 2013

Sep. 27, 2014

Jun. 28, 2014

Sep. 06, 2013

Sep. 27, 2014

Jun. 28, 2014

Nov. 08, 2013

Sep. 27, 2014

Jun. 28, 2014

Nov. 08, 2013

Sep. 27, 2014

Jun. 28, 2014

Nov. 08, 2013

Sep. 27, 2014

Jun. 28, 2014

Nov. 08, 2013

Nov. 08, 2013

Sep. 06, 2013

Jul. 28, 2013

Jul. 28, 2013

Sep. 06, 2013

2013 Term Loan due December 18, 2015 [Member]

2013 Term Loan due December 18, 2015 [Member]

2013 Term Loan due December 18, 2015 [Member]

2013 Term Loan due December 18, 2018 [Member]

2013 Term Loan due December 18, 2018 [Member]

2013 Term Loan due December 18, 2018 [Member]

1.30% Unsecured Senior Notes due November 8, 2016 [Member]

1.30% Unsecured Senior Notes due November 8, 2016 [Member]

1.30% Unsecured Senior Notes due November 8, 2016 [Member]

2.30% Unsecured Senior notes November 8, 2018 [Member]

2.30% Unsecured Senior notes November 8, 2018 [Member]

2.30% Unsecured Senior notes November 8, 2018 [Member]

4.00% Unsecured Senior Notes due November 15, 2023 [Member]

4.00% Unsecured Senior Notes due November 15, 2023 [Member]

4.00% Unsecured Senior Notes due November 15, 2023 [Member]

5.30% Unsecured Senior Notes due November 15, 2043 [Member]

5.30% Unsecured Senior Notes due November 15, 2043 [Member]

5.30% Unsecured Senior Notes due November 15, 2043 [Member]

Debt Bridge Credit Agreement [Member]

Debt Bridge Credit Agreement [Member]

Debt Bridge Credit Agreement [Member]

Cash Bridge Credit Agreement [Member]

Revolving Credit Facility [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

'

1.30%

1.30%

'

2.30%

2.30%

'

4.00%

4.00%

'

5.30%

5.30%

'

'

'

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

15-Dec-15

15-Dec-15

'

15-Dec-18

15-Dec-18

'

8-Nov-16

8-Nov-16

'

8-Nov-18

8-Nov-18

'

15-Nov-23

15-Nov-23

'

15-Nov-43

15-Nov-43

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

'

'

$400,000

'

'

$700,000

'

'

$3,100,000

'

'

$1,700,000

'

'

'

'

'

'

'

Short-term Debt

0

2,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term loans

895,000,000

930,000,000

'

1,000,000,000

300,000,000

300,000,000

300,000,000

595,000,000

630,000,000

700,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior Notes

2,294,000,000

2,294,000,000

2,300,000,000

'

'

'

'

'

'

'

499,600,000

[1]

499,600,000

[1]

'

599,300,000

[1]

599,300,000

[1]

'

796,800,000

[1]

796,800,000

[1]

'

398,300,000

[1]

398,300,000

[1]

'

'

'

'

'

'

Other financing

3,300,000

8,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total borrowings outstanding

3,192,300,000

3,234,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt, Short Term and Current Portion of Long Term

141,500,000

143,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt, less current portion

3,050,800,000

3,090,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred financing fee

26,200,000

27,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,650,000,000

1,700,000,000

600,000,000

Reduction In Credit Agreement Borrowing Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,650,000,000

1,000,000,000

'

'

'

Line of Credit Facility, Fair Value of Amount Outstanding

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

'

'

500,000,000

'

'

600,000,000

'

'

800,000,000

'

'

400,000,000

'

'

'

'

'

Borrowings Outstanding Under Securitization Program

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Private placement unsecured senior notes with registration rights discussed below collectively as the "Bonds."

Indebtedness_Extinguishment_of

Indebtedness (Extinguishment of debt) (details) (USD $)	12 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Dec. 18, 2013	Nov. 30, 2013	Dec. 27, 2013	Dec. 23, 2013	Jun. 28, 2014
		2011 Term Loan due October 26, 2016 [Member]	2.95% Unsecured Senior Notes due May 15, 2023 [Member]	2.95% Unsecured Senior Notes due May 15, 2023 [Member]	Senior Notes [Member]	Bridge Credit Agreements [Member]
			Tender Offer [Member]	Redemption [Member]
Extinguishment of Debt [Line Items]	'	'	'	'	'	'
Principal amount of debt extinguished	'	$360	'	'	'	'
Repayments of Debt	'	'	578.3	28.5	1,099.60	'
Make-whole payments	133.5	'	'	'	'	'
Write off of Deferred Debt Issuance Cost	10.5	'	'	'	'	19
Write off of Unamortized Discount	2.8	'	'	'	'	'
Gains (Losses) on Extinguishment of Debt	$165.80	'	'	'	'	'

Indebtedness_Indebtetedness_Ac

Indebtedness Indebtetedness (Accounts receivable securitization) (details) (USD $)	Sep. 27, 2014
In Millions, unless otherwise specified
Proceeds from (Repayments of) Accounts Receivable Securitization [Abstract]	'
Maximum Borrowings Under Securitization Program	$200
Securitization Program, Basis Spread on Variable Rate	0.38%
Securitization Program, Commitment Fee Percentage	0.38%

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Numerator:	'	'
Net income	$96.30	$111.40
Denominator:	'	'
Basic	133,900,000	94,200,000
Dilutive effect of share-based awards	500,000	500,000
Weighted average shares outstanding for diluted EPS	134,400,000	94,700,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	100,000	100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	186,000	264,000

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Balance at June 28, 2014	$139.60	'
OCI before reclassifications (net of tax)	-64.9	'
Amounts reclassified from AOCI (net of tax)	-0.4	'
Other Comprehensive Income (Loss), Net of Tax	-65.3	27.3
Balance as of September 27, 2014	74.3	'
Accumulated Translation Adjustment [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Balance at June 28, 2014	164.4	'
OCI before reclassifications (net of tax)	-63.8	'
Amounts reclassified from AOCI (net of tax)	0	'
Other Comprehensive Income (Loss), Net of Tax	-63.8	'
Balance as of September 27, 2014	100.6	'
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Balance at June 28, 2014	-16.1	'
OCI before reclassifications (net of tax)	-1.7	'
Amounts reclassified from AOCI (net of tax)	-0.4	'
Other Comprehensive Income (Loss), Net of Tax	-2.1	'
Balance as of September 27, 2014	-18.2	'
Accumulated Net Unrealized Investment Gain (Loss) [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Balance at June 28, 2014	2.4	'
OCI before reclassifications (net of tax)	0.6	'
Amounts reclassified from AOCI (net of tax)	0	'
Other Comprehensive Income (Loss), Net of Tax	0.6	'
Balance as of September 27, 2014	3	'
Accumulated Defined Benefit Plans Adjustment [Member]	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]	'	'
Balance at June 28, 2014	-11.1	'
OCI before reclassifications (net of tax)	0	'
Amounts reclassified from AOCI (net of tax)	0	'
Other Comprehensive Income (Loss), Net of Tax	0	'
Balance as of September 27, 2014	($11.10)	'

Income_Taxes_Details

Income Taxes (Details) (USD $)

3 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Sep. 27, 2014

Sep. 28, 2013

Jun. 28, 2014

Sep. 27, 2014

Jun. 28, 2014

Jun. 29, 2013

Jun. 30, 2012

Jun. 25, 2011

Sep. 27, 2014

Sep. 27, 2014

Sep. 28, 2013

Sep. 27, 2014

Sep. 28, 2013

Sep. 27, 2014

Sep. 27, 2014

Sep. 27, 2014

Sep. 27, 2014

Sep. 27, 2014

Israeli Holding Company Subsidiary [Member]

Israeli Holding Company Subsidiary [Member]

Israeli Holding Company Subsidiary [Member]

Israeli Holding Company Subsidiary [Member]

Israeli Holding Company Subsidiary [Member]

All Other Israel Entities [Member]

All Other Entities [Member]

ISRAEL

UNITED KINGDOM

UNITED KINGDOM

MEXICO

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Internal Revenue Service (IRS) [Member]

Israel Tax Authority [Member]

Internal Revenue Service (IRS) [Member]

Income Taxes [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective tax rate on income from continuing operations

11.40%

29.20%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective Income Tax Rate Reconciliation, Other Adjustments, Amount

'

'

'

'

'

'

'

'

'

'

($1.80)

'

$4.70

'

'

'

'

'

Foreign Statutory Corporate Tax Rate, Prior To Change, Prior Year

'

'

'

'

7.00%

7.00%

10.00%

10.00%

'

'

'

'

'

'

'

'

'

'

Foreign Statutory Corporate Tax Rate, Thereafter

'

'

'

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Foreign Statutory Corporate Tax Rate, Current Year

'

'

'

'

'

'

'

'

25.00%

'

'

21.00%

'

30.00%

'

'

'

'

Foreign Statutory Corporate Tax Rate, Year One

'

'

'

9.00%

'

'

'

'

26.50%

'

'

20.00%

'

'

'

'

'

'

Unrecognized Tax Benefits, Including Income Tax Penalties And Interest Accrued

291.5

'

205.4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized tax benefits liability, interest and penalties accrued

42.3

'

45.3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income Tax Examination, Year under Examination

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2009

'2011

'2012

'2010

Income Tax Examination, Penalties and Interest Expense

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income Tax Examination, Estimate of Possible Loss

'

'

'

'

'

'

'

'

'

$43

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014
Loss Contingencies [Line Items]	'
Loss Contingency, Damages Sought, Value	$72.50
Texas Medicaid [Member]	'
Loss Contingencies [Line Items]	'
Loss Contingency Accrual	$15

Restructuring_Details

Restructuring (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Restructuring Reserve [Roll Forward]	'	'
Beginning balance	$16.40	$2.90
Additional charges	1.7	2.1
Payments	-13.5	-1.4
Non-cash adjustments	-0.7	0
Ending balance	$3.90	$3.60

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013	Jun. 28, 2014
	segments
Segment Reporting Information [Line Items]	'	'	'
Number of Reportable Segments	5	'	'
Net sales	$951.50	$933.40	'
Operating Income (Loss)	137.2	179.7	'
Intangible assets amortization expense	106.5	29.8	'
Total Assets	13,781	5,508.80	13,880.20
Consumer Healthcare [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	493.3	538.5	'
Operating Income (Loss)	65.3	89.9	'
Intangible assets amortization expense	8.6	5.3	'
Total Assets	3,828	2,508.60	'
Nutritionals [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	125.3	129	'
Operating Income (Loss)	8.6	7.7	'
Intangible assets amortization expense	7.2	7.4	'
Total Assets	1,072.60	930.7	'
Rx Pharmaceuticals [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	194.5	203.6	'
Operating Income (Loss)	64.7	83.1	'
Intangible assets amortization expense	17	16.2	'
Total Assets	2,509.10	1,669	'
API [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	24.8	43.2	'
Operating Income (Loss)	7.1	22.4	'
Intangible assets amortization expense	0.5	0.5	'
Total Assets	251.2	295.2	'
Specialty Sciences [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	91.9	0	'
Operating Income (Loss)	14.9	0	'
Intangible assets amortization expense	72.8	0	'
Total Assets	6,023	0	'
Other Segments [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	21.7	19.1	'
Operating Income (Loss)	0.9	1.2	'
Intangible assets amortization expense	0.4	0.4	'
Total Assets	97.1	105.3	'
Segment Reconciling Items [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	0	0	'
Operating Income (Loss)	-24.3	-24.6	'
Intangible assets amortization expense	0	0	'
Total Assets	$0	$0	'

Guarantor_Financials_Guarantor

Guarantor Financials Guarantor Financials (Income statement) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Net sales	$951.50	$933.40
Cost of sales	629.7	577.1
Gross profit	321.8	356.3
Operating expenses	'	'
Distribution	14.4	13.2
Research and Development	36.6	32.3
Selling	50.4	50.2
Administration	81.5	78.8
Restructuring	1.7	2.1
Total operating expenses	184.6	176.6
Operating Income (Loss)	137.2	179.7
Interest expense, net	25.9	21.4
Other expense, (income), net	2.7	1
Income before income taxes	108.6	157.3
Income tax expense	12.3	45.9
Income (Loss) before equity in net income (loss) of subsidiaries	96.3	111.4
Equity in net income (loss) of subsidiaries	0	0
Net income	96.3	111.4
Consolidation, Eliminations [Member]	'	'
Net sales	-141.9	-145.1
Cost of sales	-121.6	-128.1
Gross profit	-20.3	-17
Operating expenses	'	'
Distribution	0	0
Research and Development	0	0
Selling	0	0
Administration	-0.5	0
Restructuring	0	0
Total operating expenses	-0.5	0
Operating Income (Loss)	-19.8	-17
Interest expense, net	-0.1	0
Other expense, (income), net	0.7	0
Income before income taxes	-20.4	-17
Income tax expense	0	0
Income (Loss) before equity in net income (loss) of subsidiaries	-20.4	-17
Equity in net income (loss) of subsidiaries	-222.7	-85.6
Net income	-243.1	-102.6
Parent Company [Member]	'	'
Net sales	0	'
Cost of sales	0	'
Gross profit	0	'
Operating expenses	'	'
Distribution	0	'
Research and Development	0	'
Selling	0	'
Administration	13.7	'
Restructuring	0	'
Total operating expenses	13.7	'
Operating Income (Loss)	-13.7	'
Interest expense, net	23.9	'
Other expense, (income), net	0	'
Income before income taxes	-37.6	'
Income tax expense	-1.6	'
Income (Loss) before equity in net income (loss) of subsidiaries	-36	'
Equity in net income (loss) of subsidiaries	132.3	'
Net income	96.3	'
Guarantor Subsidiaries [Member]	'	'
Net sales	829.7	802.1
Cost of sales	582.1	537
Gross profit	247.6	265.1
Operating expenses	'	'
Distribution	11	10.6
Research and Development	21.7	21.8
Selling	39.8	39.8
Administration	51.1	71
Restructuring	1.7	2.1
Total operating expenses	125.3	145.3
Operating Income (Loss)	122.3	119.8
Interest expense, net	192.6	20.1
Other expense, (income), net	-1.8	0.9
Income before income taxes	-68.5	98.8
Income tax expense	3.6	42.2
Income (Loss) before equity in net income (loss) of subsidiaries	-72.1	56.6
Equity in net income (loss) of subsidiaries	54.6	54.8
Net income	-17.5	111.4
Non-Guarantor Subsidiaries [Member]	'	'
Net sales	263.7	276.4
Cost of sales	169.2	168.2
Gross profit	94.5	108.2
Operating expenses	'	'
Distribution	3.4	2.6
Research and Development	14.9	10.5
Selling	10.6	10.4
Administration	17.2	7.8
Restructuring	0	0
Total operating expenses	46.1	31.3
Operating Income (Loss)	48.4	76.9
Interest expense, net	-190.5	1.3
Other expense, (income), net	3.8	0.1
Income before income taxes	235.1	75.5
Income tax expense	10.3	3.7
Income (Loss) before equity in net income (loss) of subsidiaries	224.8	71.8
Equity in net income (loss) of subsidiaries	35.8	30.8
Net income	$260.60	$102.60

Guarantor_Financials_Guarantor1

Guarantor Financials Guarantor Financial Statements (Other Comprehensive Income) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Net income	$96.30	$111.40
Foreign currency translation adjustments	-63.8	36.6
Change in fair value of derivative financial instruments, net of tax	-2.1	-9.2
Change in fair value of investment securities, net of tax	0.6	0
Post-retirement and pension liability adjustments, net of tax	0	-0.1
Other Comprehensive Income (Loss), Net of Tax	-65.3	27.3
Comprehensive income	31	138.7
Consolidation, Eliminations [Member]	'	'
Net income	-243.1	-102.6
Foreign currency translation adjustments	63.8	-37.2
Change in fair value of derivative financial instruments, net of tax	-0.4	-0.3
Change in fair value of investment securities, net of tax	-1.7	0
Post-retirement and pension liability adjustments, net of tax	0	0
Other Comprehensive Income (Loss), Net of Tax	61.7	-37.5
Comprehensive income	-181.4	-140.1
Parent Company [Member]	'	'
Net income	96.3	'
Foreign currency translation adjustments	-63.8	'
Change in fair value of derivative financial instruments, net of tax	-2.1	'
Change in fair value of investment securities, net of tax	0.6	'
Post-retirement and pension liability adjustments, net of tax	0	'
Other Comprehensive Income (Loss), Net of Tax	-65.3	'
Comprehensive income	31	'
Guarantor Subsidiaries [Member]	'	'
Net income	-17.5	111.4
Foreign currency translation adjustments	-0.2	36.6
Change in fair value of derivative financial instruments, net of tax	0.9	-9.2
Change in fair value of investment securities, net of tax	-1.3	0
Post-retirement and pension liability adjustments, net of tax	0	-0.1
Other Comprehensive Income (Loss), Net of Tax	-0.6	27.3
Comprehensive income	-18.1	138.7
Non-Guarantor Subsidiaries [Member]	'	'
Net income	260.6	102.6
Foreign currency translation adjustments	-63.6	37.2
Change in fair value of derivative financial instruments, net of tax	-0.5	0.3
Change in fair value of investment securities, net of tax	3	0
Post-retirement and pension liability adjustments, net of tax	0	0
Other Comprehensive Income (Loss), Net of Tax	-61.1	37.5
Comprehensive income	$199.50	$140.10

Guarantor_Financials_Guarantor2

Guarantor Financials Guarantor Financials (Balance Sheet) details (Details) (USD $)	Sep. 27, 2014	Jun. 28, 2014	Sep. 28, 2013	Jun. 29, 2013
In Millions, unless otherwise specified
Assets	'	'	'	'
Cash and cash equivalents, beginning of period	$891.50	$799.50	$816.60	$779.90
Investment securities	21.6	5.9	'	'
Accounts Receivable, Net	869.4	935.1	'	'
Inventories	656.8	631.6	'	'
Current deferred income taxes	64.6	62.8	'	'
Prepaid expenses and other current assets	130.1	116	'	'
Total current assets	2,634	2,550.90	'	'
Property and Equipment, Net	761.7	779.9	'	'
Goodwill and other indefinite-lived intangible assets	3,503	3,543.80	'	'
Other intangible assets, net	6,671.80	6,787	'	'
Non-current deferred income taxes	28.5	23.6	'	'
Other non-current assets	182	195	'	'
Intercompany loans receivable	0	0	'	'
Investments in subsidiaries	0	0	'	'
Total non-current assets	11,147	11,329.30	'	'
Total Assets	13,781	13,880.20	5,508.80	'
Liabilities and Shareholders' Equity	'	'	'	'
Accounts Payable	309	364.3	'	'
Short-term Debt	0	2.1	'	'
Payroll and related taxes	77	112.3	'	'
Accrued Customer Programs	274.5	256.5	'	'
Accrued Liabilities	179.9	179.4	'	'
Accrued Income Taxes	31.7	17.4	'	'
Current deferred income taxes	4.3	1.1	'	'
Current portion of long-term debt	141.5	141.6	'	'
Total current liabilities	1,017.90	1,074.70	'	'
Long-term debt, less current portion	3,050.80	3,090.50	'	'
Non-current deferred income taxes	708.7	727.9	'	'
Other non-current liabilities	286.9	293.4	'	'
Intercompany loans payable	0	0	'	'
Total non-current liabilities	4,046.40	4,111.80	'	'
Liabilities	5,064.30	5,186.50	'	'
Controlling interest	8,716.70	8,692.90	'	'
Noncontrolling interest	0	0.8	'	'
Shareholders' equity	8,716.70	8,693.70	'	'
Total liabilities and shareholders' equity	13,781	13,880.20	'	'
Consolidation, Eliminations [Member]	'	'	'	'
Assets	'	'	'	'
Cash and cash equivalents, beginning of period	0	0	0	0
Investment securities	0	0	'	'
Accounts Receivable, Net	-1,238.20	-4,025.90	'	'
Inventories	-149.7	-130.4	'	'
Current deferred income taxes	0	0	'	'
Prepaid expenses and other current assets	0	0	'	'
Total current assets	-1,387.90	-4,156.30	'	'
Property and Equipment, Net	0	0	'	'
Goodwill and other indefinite-lived intangible assets	0	0	'	'
Other intangible assets, net	0	0	'	'
Non-current deferred income taxes	0	-16	'	'
Other non-current assets	0	0	'	'
Intercompany loans receivable	-23,608	-20,889.80	'	'
Investments in subsidiaries	-15,190.70	-14,371	'	'
Total non-current assets	-38,798.70	-35,276.80	'	'
Total Assets	-40,186.60	-39,433.10	'	'
Liabilities and Shareholders' Equity	'	'	'	'
Accounts Payable	-1,237.60	-4,156.20	'	'
Short-term Debt	'	0	'	'
Payroll and related taxes	0	0	'	'
Accrued Customer Programs	0	0	'	'
Accrued Liabilities	-0.4	-0.5	'	'
Accrued Income Taxes	0	0	'	'
Current deferred income taxes	0	0	'	'
Current portion of long-term debt	0	0	'	'
Total current liabilities	-1,238	-4,156.70	'	'
Long-term debt, less current portion	0	0	'	'
Non-current deferred income taxes	0	-16	'	'
Other non-current liabilities	0	0	'	'
Intercompany loans payable	-23,608	-20,888.30	'	'
Total non-current liabilities	-23,608	-20,904.30	'	'
Liabilities	-24,846	-25,061	'	'
Controlling interest	'	-14,372.10	'	'
Noncontrolling interest	'	0	'	'
Shareholders' equity	-15,340.60	-14,372.10	'	'
Total liabilities and shareholders' equity	-40,186.60	-39,433.10	'	'
Parent Company [Member]	'	'	'	'
Assets	'	'	'	'
Cash and cash equivalents, beginning of period	424.7	323.4	'	'
Investment securities	0	0	'	'
Accounts Receivable, Net	2	1.4	'	'
Inventories	0	0	'	'
Current deferred income taxes	0	0	'	'
Prepaid expenses and other current assets	20.6	9.9	'	'
Total current assets	447.3	334.7	'	'
Property and Equipment, Net	0	0	'	'
Goodwill and other indefinite-lived intangible assets	0	0	'	'
Other intangible assets, net	0	0	'	'
Non-current deferred income taxes	14.4	16	'	'
Other non-current assets	23	23.8	'	'
Intercompany loans receivable	7,300	7,300	'	'
Investments in subsidiaries	6,284.90	6,218.90	'	'
Total non-current assets	13,622.30	13,558.70	'	'
Total Assets	14,069.60	13,893.40	'	'
Liabilities and Shareholders' Equity	'	'	'	'
Accounts Payable	40.4	35.2	'	'
Short-term Debt	'	0	'	'
Payroll and related taxes	0.1	0.1	'	'
Accrued Customer Programs	0	0	'	'
Accrued Liabilities	32.5	11.4	'	'
Accrued Income Taxes	-0.6	0	'	'
Current deferred income taxes	0	0	'	'
Current portion of long-term debt	140	140	'	'
Total current liabilities	212.4	186.7	'	'
Long-term debt, less current portion	3,049.20	3,084	'	'
Non-current deferred income taxes	0	0	'	'
Other non-current liabilities	0	0	'	'
Intercompany loans payable	2,091.30	1,929	'	'
Total non-current liabilities	5,140.50	5,013	'	'
Liabilities	5,352.90	5,199.70	'	'
Controlling interest	'	8,693.70	'	'
Noncontrolling interest	'	0	'	'
Shareholders' equity	8,716.70	8,693.70	'	'
Total liabilities and shareholders' equity	14,069.60	13,893.40	'	'
Guarantor Subsidiaries [Member]	'	'	'	'
Assets	'	'	'	'
Cash and cash equivalents, beginning of period	233.6	245.2	511.4	519.6
Investment securities	16.5	0	'	'
Accounts Receivable, Net	283	463.9	'	'
Inventories	658.4	613.9	'	'
Current deferred income taxes	61.3	59.8	'	'
Prepaid expenses and other current assets	60.1	62.7	'	'
Total current assets	1,312.90	1,445.50	'	'
Property and Equipment, Net	526.4	532.4	'	'
Goodwill and other indefinite-lived intangible assets	3,065.30	3,078.30	'	'
Other intangible assets, net	6,475.40	6,583.80	'	'
Non-current deferred income taxes	10.9	0	'	'
Other non-current assets	74.5	84.5	'	'
Intercompany loans receivable	2,065.70	2,145.70	'	'
Investments in subsidiaries	8,538.30	7,826.90	'	'
Total non-current assets	20,756.50	20,251.60	'	'
Total Assets	22,069.40	21,697.10	'	'
Liabilities and Shareholders' Equity	'	'	'	'
Accounts Payable	1,254	3,998	'	'
Short-term Debt	'	0	'	'
Payroll and related taxes	56.2	79.9	'	'
Accrued Customer Programs	35	65.6	'	'
Accrued Liabilities	102.2	121.8	'	'
Accrued Income Taxes	12.7	3.4	'	'
Current deferred income taxes	4.3	1.1	'	'
Current portion of long-term debt	1.5	1.6	'	'
Total current liabilities	1,465.90	4,271.40	'	'
Long-term debt, less current portion	1.6	1.9	'	'
Non-current deferred income taxes	692.2	709.6	'	'
Other non-current liabilities	192.4	182.6	'	'
Intercompany loans payable	13,849	11,291.50	'	'
Total non-current liabilities	14,735.20	12,185.60	'	'
Liabilities	16,201.10	16,457	'	'
Controlling interest	'	5,240.10	'	'
Noncontrolling interest	'	0	'	'
Shareholders' equity	5,868.30	5,240.10	'	'
Total liabilities and shareholders' equity	22,069.40	21,697.10	'	'
Non-Guarantor Subsidiaries [Member]	'	'	'	'
Assets	'	'	'	'
Cash and cash equivalents, beginning of period	233.2	230.9	305.2	260.3
Investment securities	5.1	5.9	'	'
Accounts Receivable, Net	1,822.60	4,495.70	'	'
Inventories	148.1	148.1	'	'
Current deferred income taxes	3.3	3	'	'
Prepaid expenses and other current assets	49.4	43.4	'	'
Total current assets	2,261.70	4,927	'	'
Property and Equipment, Net	235.3	247.5	'	'
Goodwill and other indefinite-lived intangible assets	437.7	465.5	'	'
Other intangible assets, net	196.4	203.2	'	'
Non-current deferred income taxes	3.2	23.6	'	'
Other non-current assets	84.5	86.7	'	'
Intercompany loans receivable	14,242.30	11,444.10	'	'
Investments in subsidiaries	367.5	325.2	'	'
Total non-current assets	15,566.90	12,795.80	'	'
Total Assets	17,828.60	17,722.80	'	'
Liabilities and Shareholders' Equity	'	'	'	'
Accounts Payable	252.2	487.3	'	'
Short-term Debt	'	2.1	'	'
Payroll and related taxes	20.7	32.3	'	'
Accrued Customer Programs	239.5	190.9	'	'
Accrued Liabilities	45.6	46.7	'	'
Accrued Income Taxes	19.6	14	'	'
Current deferred income taxes	0	0	'	'
Current portion of long-term debt	0	0	'	'
Total current liabilities	577.6	773.3	'	'
Long-term debt, less current portion	0	4.6	'	'
Non-current deferred income taxes	16.5	34.3	'	'
Other non-current liabilities	94.5	110.8	'	'
Intercompany loans payable	7,667.70	7,667.80	'	'
Total non-current liabilities	7,778.70	7,817.50	'	'
Liabilities	8,356.30	8,590.80	'	'
Controlling interest	'	9,131.20	'	'
Noncontrolling interest	'	0.8	'	'
Shareholders' equity	9,472.30	9,132	'	'
Total liabilities and shareholders' equity	$17,828.60	$17,722.80	'	'

Guarantor_Financials_Guarantor3

Guarantor Financials Guarantor Financials (cash flows) details (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Sep. 28, 2013
Net Cash Provided by (Used in) Operating Activities	$195.10	$98.70
Cash Flows (For) From Investing Activities	'	'
Additions to property and equipment	-31.7	-40.4
(Purchase) return of Investments	-0.1	0
Proceeds from sale of business	1.1	0
Proceeds from sale of land	0	4.6
Intercompany notes issued	0	'
Net cash from (for) investing activities	-30.7	-35.8
Cash Flows (For) From Financing Activities	'	'
Repayments of long-term debt	-39.5	0
Cash dividends	-14.1	-8.5
Payments for Repurchase of Common Stock	7.5	7.3
Settlements of contingent consideration	-5	0
Borrowings (repayments) of short-term debt, net	-2.1	1.1
Issuance of Common Stock	2.6	3.5
Excess tax benefit of stock transactions	4.3	7.2
Payments of Financing Costs	0	24.8
Intercompany notes borrowed	0	'
Net cash from (for) financing activities	-61.3	-28.8
Effect of exchange rate changes on cash	-11.1	2.6
Cash and Cash Equivalents, Period Increase (Decrease)	92	36.7
Cash and cash equivalents, beginning of period	799.5	779.9
Cash and cash equivalents, end of period	891.5	816.6
Consolidation, Eliminations [Member]	'	'
Net Cash Provided by (Used in) Operating Activities	0	0
Cash Flows (For) From Investing Activities	'	'
Additions to property and equipment	0	0
(Purchase) return of Investments	0	'
Proceeds from sale of business	0	'
Proceeds from sale of land	'	0
Intercompany notes issued	-445.7	'
Net cash from (for) investing activities	445.7	0
Cash Flows (For) From Financing Activities	'	'
Repayments of long-term debt	0	'
Cash dividends	0	0
Payments for Repurchase of Common Stock	0	0
Settlements of contingent consideration	0	'
Borrowings (repayments) of short-term debt, net	0	0
Issuance of Common Stock	0	0
Excess tax benefit of stock transactions	0	0
Payments of Financing Costs	'	0
Intercompany notes borrowed	-445.7	'
Net cash from (for) financing activities	-445.7	0
Effect of exchange rate changes on cash	0	0
Cash and Cash Equivalents, Period Increase (Decrease)	0	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	0	0
Parent Company [Member]	'	'
Net Cash Provided by (Used in) Operating Activities	-91.2	'
Cash Flows (For) From Investing Activities	'	'
Additions to property and equipment	0	'
(Purchase) return of Investments	0	'
Proceeds from sale of business	0	'
Intercompany notes issued	0	'
Net cash from (for) investing activities	0	'
Cash Flows (For) From Financing Activities	'	'
Repayments of long-term debt	-35	'
Cash dividends	-14.1	'
Payments for Repurchase of Common Stock	7.5	'
Settlements of contingent consideration	0	'
Borrowings (repayments) of short-term debt, net	0	'
Issuance of Common Stock	2.6	'
Excess tax benefit of stock transactions	4.3	'
Intercompany notes borrowed	242.2	'
Net cash from (for) financing activities	192.5	'
Effect of exchange rate changes on cash	0	'
Cash and Cash Equivalents, Period Increase (Decrease)	101.3	'
Cash and cash equivalents, beginning of period	323.4	'
Cash and cash equivalents, end of period	424.7	'
Guarantor Subsidiaries [Member]	'	'
Net Cash Provided by (Used in) Operating Activities	211.3	52.9
Cash Flows (For) From Investing Activities	'	'
Additions to property and equipment	-18.4	-31.2
(Purchase) return of Investments	1.2	'
Proceeds from sale of business	0	'
Proceeds from sale of land	'	0
Intercompany notes issued	202.1	'
Net cash from (for) investing activities	-219.3	-31.2
Cash Flows (For) From Financing Activities	'	'
Repayments of long-term debt	0	'
Cash dividends	0	-8.5
Payments for Repurchase of Common Stock	0	7.3
Settlements of contingent consideration	-5	'
Borrowings (repayments) of short-term debt, net	0	0
Issuance of Common Stock	0	3.5
Excess tax benefit of stock transactions	0	7.2
Payments of Financing Costs	'	24.8
Intercompany notes borrowed	1.4	'
Net cash from (for) financing activities	-3.6	-29.9
Effect of exchange rate changes on cash	0	0
Cash and Cash Equivalents, Period Increase (Decrease)	-11.6	-8.2
Cash and cash equivalents, beginning of period	245.2	519.6
Cash and cash equivalents, end of period	233.6	511.4
Non-Guarantor Subsidiaries [Member]	'	'
Net Cash Provided by (Used in) Operating Activities	75	45.8
Cash Flows (For) From Investing Activities	'	'
Additions to property and equipment	-13.3	-9.2
(Purchase) return of Investments	-1.3	'
Proceeds from sale of business	1.1	'
Proceeds from sale of land	'	4.6
Intercompany notes issued	243.6	'
Net cash from (for) investing activities	-257.1	-4.6
Cash Flows (For) From Financing Activities	'	'
Repayments of long-term debt	-4.5	'
Cash dividends	0	0
Payments for Repurchase of Common Stock	0	0
Settlements of contingent consideration	0	'
Borrowings (repayments) of short-term debt, net	-2.1	1.1
Issuance of Common Stock	0	0
Excess tax benefit of stock transactions	0	0
Payments of Financing Costs	'	0
Intercompany notes borrowed	202.1	'
Net cash from (for) financing activities	195.5	1.1
Effect of exchange rate changes on cash	-11.1	2.6
Cash and Cash Equivalents, Period Increase (Decrease)	2.3	44.9
Cash and cash equivalents, beginning of period	230.9	260.3
Cash and cash equivalents, end of period	$233.20	$305.20

Subsequent_events_Subsequent_e

Subsequent events Subsequent events (Details) (USD $)

Sep. 27, 2014

Jun. 28, 2014

Sep. 06, 2013

Oct. 31, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Nov. 06, 2014

Lumara [Member]

Omega [Member]

Omega [Member]

Euro Member Countries, Euro

Euro Member Countries, Euro

United States of America, Dollars

5.1045% Senior Note [Member]

5.1045% Senior Note [Member]

5.1045% Senior Note [Member]

6.19% Senior Note [Member]

6.19% Senior Note [Member]

6.19% Senior Note [Member]

6.19% Senior Note [Member]

5.125% Retail Bond [Member]

5.125% Retail Bond [Member]

5.125% Retail Bond [Member]

4.5% Retail Bond [Member]

4.5% Retail Bond [Member]

4.5% Retail Bond [Member]

5.0% Retail Bond [Member]

5.0% Retail Bond [Member]

5.0% Retail Bond [Member]

Credit facility indebtedness [Member]

Consideration for business acquisition [Member]

Non-solicit agreement [Member]

Noncompete Agreements [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Omega [Member]

Omega [Member]

Omega [Member]

Omega [Member]

Omega [Member]

Euro Member Countries, Euro

Omega [Member]

Omega [Member]

Euro Member Countries, Euro

United States of America, Dollars

Omega [Member]

Omega [Member]

Euro Member Countries, Euro

Omega [Member]

Omega [Member]

Euro Member Countries, Euro

Omega [Member]

Omega [Member]

Euro Member Countries, Euro

Euro Member Countries, Euro

Omega [Member]

Omega [Member]

Omega [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Omega [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Omega [Member]

Omega [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Omega [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Omega [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Omega [Member]

Omega [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event Type [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to Acquire Businesses, Gross

'

'

'

$83,000,000

$3,600,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Company shares issued to acquired company shareholders

'

'

'

'

'

5,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Expense, Other

'

'

'

'

'

'

2,480,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Escrow Deposit Disbursements Related to Property Acquisition

'

'

'

'

'

'

248,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

'

'

'

'

'

'

'

1,100,000,000

'

'

'

135,000,000

'

'

16,200,000

20,000,000

'

'

300,000,000

'

'

180,000,000

'

'

120,000,000

390,000,000

'

'

'

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'3 years

Business Acquisition, Cash Exchange

'

'

'

'

'

1,800,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

'

5.10%

'

'

6.19%

'

'

'

5.13%

'

'

4.50%

'

'

5.00%

'

'

5.00%

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

'

1-Jan-23

'

'

1-Jan-16

'

'

'

1-Jan-17

'

'

1-Jan-17

'

'

1-Jan-19

'

'

'

'

'

'

Business Acquisition, Percentage of Voting Interests Acquired

'

'

'

'

'

95.77%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Treasury Stock, Shares, Acquired

'

'

'

'

30,243,983

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Date of Acquisition Agreement

'

'

'

31-Oct-14

6-Nov-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Expiration Period

'

'

'

'

'364 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquired company shares outstanding on acquisition date

'

'

'

'

'

685,348,257

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

'

1,750,000,000

1,000,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term loans

$895,000,000

$930,000,000

$1,000,000,000

'

'

'

'

$800,000,000

$300,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'